Osteoarthritis: Epidemiology, Pathogenesis, and Treatment

Abstract

Osteoarthritis (OA) is the most common chronic joint disorder and a major cause of disability worldwide. Once regarded as a consequence of cartilage wear, OA is now recognized as a complex whole-joint disease involving coordinated pathological changes in articular cartilage, synovium, and subchondral bone. Disease progression is driven by chronic low-grade inflammation, metabolic dysregulation, oxidative stress, and abnormal cellular responses to mechanical stress. These processes are mediated by interconnected signaling networks that regulate inflammatory responses, extracellular matrix (ECM) metabolism, and tissue remodeling. Epigenetic mechanisms, such as DNA methylation, histone modifications, and noncoding RNAs, are increasingly recognized as regulators of OA-related gene expression. However, how signaling networks integrate with epigenetic regulation, particularly histone methylation, remains incompletely understood. In this review, we summarize the epidemiological burden and major risk factors of OA, describe pathological remodeling across joint tissues, and discuss key signaling pathways involved in OA pathogenesis before outlining epigenetic mechanisms. We also highlight the role of histone methylation in inflammation, metabolic imbalance, and tissue remodeling, and summarize current nonpharmacological, pharmacological, injectable, and surgical treatment strategies. Together, this review provides an integrated overview of the epidemiology, pathogenesis, and treatment of OA.

Keywords

epidemiology / epigenetic regulation / histone methylation / osteoarthritis / signaling pathways / therapy

References

[1] A. Bortoluzzi, F. Furini, and C. A. Scirè, “Osteoarthritis and Its Management—Epidemiology, Nutritional Aspects and Environmental Factors,” Autoimmunity Reviews 17, no. 11 (2018): 1097–1104.

[2] S. Semenistaja, S. Skuja, A. Kadisa, and V. Groma, “Healthy and Osteoarthritis-Affected Joints Facing the Cellular Crosstalk,” International Journal of Molecular Sciences 24, no. 4 (2023): 4120.

[3] M. Guan, Q. Yu, G. Zhou, et al., “Mechanisms of Chondrocyte Cell Death in Osteoarthritis: Implications for Disease Progression and Treatment,” Journal of Orthopaedic Surgery and Research 19, no. 1 (2024): 550.

[4] X. Wu, X. Fan, R. Crawford, Y. Xiao, and I. Prasadam, “The Metabolic Landscape in Osteoarthritis,” Aging and Disease 13, no. 4 (2022): 1166–1182.

[5] L. Wu, X. Huang, L. Li, H. Huang, R. Xu, and W. Luyten, “Insights on Biology and Pathology of HIF-1α/-2α, TGFβ/BMP, Wnt/β-catenin, and NF-κB Pathways in Osteoarthritis,” Current Pharmaceutical Design 18, no. 22 (2012): 3293–3312.

[6] Q. Yao, X. Wu, C. Tao, et al., “Osteoarthritis: Pathogenic Signaling Pathways and Therapeutic Targets,” Signal Transduction and Targeted Therapy 8, no. 1 (2023): 56.

[7] A. J. Knights, S. J. Redding, and T. Maerz, “Inflammation in Osteoarthritis: The Latest Progress and Ongoing Challenges,” Current Opinion in Rheumatology 35, no. 2 (2023): 128–134.

[8] A. L. Arruda, G. Katsoula, S. Chen, E. Reimann, P. Kreitmaier, and E. Zeggini, “The Genetics and Functional Genomics of Osteoarthritis,” Annual Review of Genomics and Human Genetics 25, no. 1 (2024): 239–257.

[9] L. Oton-Gonzalez, C. Mazziotta, M. R. Iaquinta, et al., “Genetics and Epigenetics of Bone Remodeling and Metabolic Bone Diseases,” International Journal of Molecular Sciences 23, no. 3 (2022): 1500.

[10] A. Latourte, M. Kloppenburg, and P. Richette, “Emerging Pharmaceutical Therapies for Osteoarthritis,” Nature Reviews Rheumatology 16, no. 12 (2020): 673–688.

[11] L. Tong, H. Yu, X. Huang, et al., “Current Understanding of Osteoarthritis Pathogenesis and Relevant New Approaches,” Bone Research 10, no. 1 (2022): 60.

[12] H. Z. Li, X. Z. Liang, Y. Q. Sun, H. F. Jia, J. C. Li, and G. Li, “Global, Regional, and National Burdens of Osteoarthritis From 1990 to 2021: Findings From the 2021 Global Burden of Disease Study,” Frontiers in Medicine (Lausanne) 11 (2024): 1476853.

[13] Z. Wang, Z. Xiao, C. Sun, G. Xu, and J. He, “Global, Regional and National Burden of Osteoarthritis in 1990–2021: A Systematic Analysis of the Global Burden of Disease Study 2021,” BMC Musculoskeletal Disorders [Electronic Resource] 25, no. 1 (2024): 1021.

[14] A. Courties, I. Kouki, N. Soliman, S. Mathieu, and J. Sellam, “Osteoarthritis Year in Review 2024: Epidemiology and Therapy,” Osteoarthritis and Cartilage 32, no. 11 (2024): 1397–1404.

[15] E. Li, J. Tan, K. Xu, Y. Pan, and P. Xu, “Global Burden and Socioeconomic Impact of Knee Osteoarthritis: A Comprehensive Analysis,” Frontiers in Medicine (Lausanne) 11 (2024): 1323091.

[16] Global, Regional, and National Burden of Osteoarthritis, 1990–2020 and Projections to 2050: A Systematic Analysis for the Global Burden of Disease Study 2021. The Lancet Rheumatology 2023; 5(9): e508–e522.

[17] H. Xu, W. Xiao, C. Ding, et al., “Global Burden of Osteoarthritis Among Postmenopausal Women in 204 Countries and territories: A Systematic Analysis for the Global Burden of Disease Study 2021,” BMJ Global Health 10, no. 3 (2025): e017198.

[18] L. Wang and Y. Ye, “Trends and Projections of the Burden of Osteoarthritis Disease in China and Globally: A Comparative Study of the 2019 Global Burden of Disease Database,” Preventive Medicine Reports 37 (2024): 102562.

[19] H. Long, Q. Liu, H. Yin, et al., “Prevalence Trends of Site-Specific Osteoarthritis from 1990 to 2019: Findings from the Global Burden of Disease Study 2019,” Arthritis & Rheumatology 74, no. 7 (2022): 1172–1183.

[20] J. M. Wilfong, E. M. Badley, and A. V. Perruccio, “Old before Their Time? The Impact of Osteoarthritis on Younger Adults,” Arthritis Care & Research (Hoboken) 76, no. 10 (2024): 1400–1408.

[21] Y. He, W. Jiang, and W. Wang, “Global Burden of Osteoarthritis in Adults Aged 30 to 44 Years, 1990 to 2019: Results From the Global Burden of Disease Study 2019,” BMC Musculoskeletal Disorders [Electronic Resource] 25, no. 1 (2024): 303.

[22] X. Xie, K. Zhang, Y. Li, et al., “Global, Regional, and National Burden of Osteoarthritis From 1990 to 2021 and Projections to 2035: A Cross-sectional Study for the Global Burden of Disease Study 2021,” PLoS ONE 20, no. 5 (2025): e0324296.

[23] L. Qiao, M. Li, F. Deng, et al., “Epidemiological Trends of Osteoarthritis at the Global, Regional, and National Levels From 1990 to 2021 and Projections to 2050,” Arthritis Research & Therapy 27, no. 1 (2025): 199.

[24] A. Dell'Isola, F. Recenti, B. Giardulli, B. J. Lawford, and A. Kiadaliri, “Osteoarthritis Year in Review 2025: Epidemiology and Therapy,” Osteoarthritis and Cartilage 33, no. 11 (2025): 1300–1306.

[25] R. F. Loeser, “Aging and Osteoarthritis: The Role of Chondrocyte Senescence and Aging Changes in the Cartilage Matrix,” Osteoarthritis and Cartilage 17, no. 8 (2009): 971–979.

[26] A. Litwic, M. H. Edwards, E. M. Dennison, and C. Cooper, “Epidemiology and Burden of Osteoarthritis,” British Medical Bulletin 105 (2013): 185–199.

[27] B. O. Diekman and R. F. Loeser, “Aging and the Emerging Role of Cellular Senescence in Osteoarthritis,” Osteoarthritis and Cartilage 32, no. 4 (2024): 365–371.

[28] J. Zhou, J. Huang, Z. Li, et al., “Identification of Aging-related Biomarkers and Immune Infiltration Characteristics in Osteoarthritis Based on Bioinformatics Analysis and Machine Learning,” Frontiers in Immunology 14 (2023): 1168780.

[29] C. Reyes, K. M. Leyland, G. Peat, C. Cooper, N. K. Arden, and D. Prieto-Alhambra, “Association between Overweight and Obesity and Risk of Clinically Diagnosed Knee, Hip, and Hand Osteoarthritis: A Population-Based Cohort Study,” Arthritis Rheumatology 68, no. 8 (2016): 1869–1875.

[30] Y. Dong, Y. Yan, J. Zhou, Q. Zhou, and H. Wei, “Evidence on Risk Factors for Knee Osteoarthritis in Middle-older Aged: A Systematic Review and Meta Analysis,” Journal of Orthopaedic Surgery and Research 18, no. 1 (2023): 634.

[31] Q. Wu, Z. Xu, X. Ma, et al., “Association of Low Muscle Mass Index and Sarcopenic Obesity With Knee Osteoarthritis: A Systematic Review and Meta-analysis,” Journal of the International Society of Sports Nutrition 21, no. 1 (2024): 2352393.

[32] D. F. McWilliams, B. F. Leeb, S. G. Muthuri, M. Doherty, and W. Zhang, “Occupational Risk Factors for Osteoarthritis of the Knee: A Meta-analysis,” Osteoarthritis and Cartilage 19, no. 7 (2011): 829–839.

[33] I. J. Wallace, S. Worthington, D. T. Felson, et al., “Knee Osteoarthritis Has Doubled in Prevalence Since the Mid-20th Century,” Proceedings of the National Academy of Sciences of the United States of America 114, no. 35 (2017): 9332–9336.

[34] J. Du, X. Sun, L. Ao, et al., “Impact of Abnormal Mechanical Stress on Chondrocyte Death in Osteoarthritis,” Medical Science Monitor 31 (2025): e948290.

[35] K. Bo, X. Xie, X. Liu, et al., “Predicting Incident Radiographic Knee osteoarthritis Through Quantitative Meniscal Lesion Parameters: Data From the osteoarthritis initiative,” BMC Musculoskeletal Disorders [Electronic Resource] 25, no. 1 (2024): 626.

[36] O. R. Bayliss Zajdman, T. E. Flaxman, H. J. Bigham, and D. L. Benoit, “Females With Knee Osteoarthritis Use a Detrimental Knee Loading Strategy When Squatting,” The Knee 38 (2022): 9–18.

[37] M. Peshkova, A. Lychagin, M. Lipina, et al., “Gender-Related Aspects in Osteoarthritis Development and Progression: A Review,” International Journal of Molecular Sciences 23, no. 5 (2022): 2767.

[38] A. Atasoy-Zeybek, K. K. Showel, C. V. Nagelli, J. J. Westendorf, and C. H. Evans, “The Intersection of Aging and Estrogen in Osteoarthritis,” NPJ Womens Health 3, no. 1 (2025): 15.

[39] Y. Sun, P. Leng, P. Guo, et al., “G Protein Coupled Estrogen Receptor Attenuates Mechanical Stress-mediated Apoptosis of Chondrocyte in Osteoarthritis via Suppression of Piezo1,” Molecular Medicine 27, no. 1 (2021): 96.

[40] A. Economou, I. Mallia, A. Fioravanti, et al., “The Role of Adipokines Between Genders in the Pathogenesis of Osteoarthritis,” International Journal of Molecular Sciences 25, no. 19 (2024): 10865.

[41] M. Maniglio, L. Loisay, D. de Haro, A. Antoniadis, T. Hügle, and J. Geurts, “Subchondral Bone Marrow Adipose Tissue Lipolysis Regulates Bone Formation in Hand Osteoarthritis,” Osteoarthritis and Cartilage 33, no. 3 (2025): 322–329.

[42] K. Sun, J. Guo, X. Yao, Z. Guo, and F. Guo, “Growth Differentiation Factor 5 in Cartilage and Osteoarthritis: A Possible Therapeutic Candidate,” Cell Proliferation 54, no. 3 (2021): e12998.

[43] Y. C. Chen, Y. C. Wang, M. C. Lee, et al., “Decisive Gene Strategy on Osteoarthritis: A Comprehensive Whole-literature Based Approach for Conclusive Gene Targets,” Aging (Albany NY) 16, no. 17 (2024): 12346–12378.

[44] P. Wang, F. Duan, Y. Lv, S. Man, S. Liu, and Y. Liu, “Long- and Intermediate-Term Ambient Particulate Pollution Is Associated With Increased Osteoarthritis Risk: A Population-Based Prospective Analysis,” Environmental Science & Technology 58, no. 22 (2024): 9536–9547.

[45] Y. Wang, Y. Zhang, C. Zhao, W. Cai, Z. Wang, and W. Zhao, “Physical Activity, Sedentary Behavior, and Osteoarthritis: A Two-Sample Mendelian Randomization Analysis,” Iranian Journal of Public Health 52, no. 10 (2023): 2099–2108.

[46] T. Uematsu, S. Nojiri, M. Ishijima, and Y. Nishizaki, “Association Between Osteoarthritis and Cardiovascular Disease in Elderly in Japan: An Administrative Claims Database Analysis,” BMJ Open 14, no. 3 (2024): e080387.

[47] W. Liu, N. Balu, G. Canton, et al., “Understanding Atherosclerosis through an Osteoarthritis Data Set,” Arteriosclerosis, Thrombosis, and Vascular Biology 39, no. 6 (2019): 1018–1025.

[48] Z. J. Yang, Y. Liu, Y. L. Liu, et al., “Osteoarthritis and Hypertension: Observational and Mendelian Randomization Analyses,” Arthritis Research & Therapy 26, no. 1 (2024): 88.

[49] X. Liang, O. H. I. Chou, C. L. Cheung, and B. M. Y. Cheung, “Is Hypertension Associated With Arthritis? The United States National Health and Nutrition Examination Survey 1999–2018,” Annals of Medicine 54, no. 1 (2022): 1767–1775.

[50] G. S. Fernandes and A. M. Valdes, “Cardiovascular Disease and Osteoarthritis: Common Pathways and Patient Outcomes,” European Journal of Clinical Investigation 45, no. 4 (2015): 405–414.

[51] K. Ching, X. Houard, F. Berenbaum, and C. Wen, “Hypertension Meets Osteoarthritis—revisiting the Vascular Aetiology Hypothesis,” Nature Reviews Rheumatology 17, no. 9 (2021): 533–549.

[52] Y. Yang, X. Liang, H. Luo, et al., “Assessment of Aortic and Peripheral Arterial Stiffness in Patients With Knee Osteoarthritis by Ultrasound Doppler Derived Pulse Wave Velocity,” Scientific Reports 14, no. 1 (2024): 1346.

[53] M. A. Rabie, H. Madry, M. Cucchiarini, and N. S. El-Sayed, “The Brain-joint Axis: Links Between Osteoarthritis and Neurodegenerative Disorders in Aging,” Journal of Advanced Research (2025): S2090–1232(25)00819–00817, https://doi.org/10.1016/j.jare.2025.10.023.

[54] Y. Liu, X. Zhou, C. Chen, et al., “Association Between Osteoarthritis With Parkinson's Disease in the US (NHANES 2011–2020),” Frontiers in Neuroscience 18 (2024): 1393740.

[55] R. Guo, Y. N. Ou, L. Y. Ma, et al., “Osteoarthritis, Osteoarthritis Treatment and Risk of Incident Dementia: A Prospective Cohort Study Based on UK Biobank,” Age and Ageing 53, no. 8 (2024): afae167.

[56] J. Di, Y. Xi, Y. Liu, et al., “Unraveling the Controversy: The Causal Link between Osteoarthritis and Alzheimer's Disease,” Brain and Behavior 15, no. 3 (2025): e70455.

[57] I. O. Umoh, H. J. Dos Reis, and A. C. P. de Oliveira, “Molecular Mechanisms Linking Osteoarthritis and Alzheimer's Disease: Shared Pathways, Mechanisms and Breakthrough Prospects,” International Journal of Molecular Sciences 25, no. 5 (2024): 3044.

[58] H. Xu, J. Wei, D. Chen, Y. Li, and Q. Shen, “Assessing Causality Between Osteoarthritis and Gastrointestinal Disorders: A Mendelian Randomization Study,” Scientific Reports 13, no. 1 (2023): 19603.

[59] M. Zhang, H. Li, Q. Li, et al., “Osteoarthritis With Depression: Mapping Publication Status and Exploring Hotspots,” Frontiers in Psychology 15 (2024): 1457625.

[60] J. Liu, H. Jin, and D. K. Yon, “Risk Factors for Depression in Patients With Knee Osteoarthritis: A Systematic Review and Meta-analysis,” Orthopedics 47, no. 5 (2024): e225–e232.

[61] Q. Feng, M. Weng, X. Yang, and M. Zhang, “Anxiety and Depression Prevalence and Associated Factors in Patients With Knee Osteoarthritis,” Frontiers in Psychology 15 (2024): 1483570.

[62] W. Yang, G. Ma, J. Li, et al., “Anxiety and Depression as Potential Risk Factors for Limited Pain Management in Patients With Elderly Knee Osteoarthritis: A Cross-lagged Study,” BMC Musculoskeletal Disorders [Electronic Resource] 25, no. 1 (2024): 995.

[63] S. Swain, A. Sarmanova, C. Coupland, M. Doherty, and W. Zhang, “Comorbidities in Osteoarthritis: A Systematic Review and Meta-Analysis of Observational Studies,” Arthritis Care Research (Hoboken) 72, no. 7 (2020): 991–1000.

[64] C. Scarpignato, A. Lanas, C. Blandizzi, et al., “Safe Prescribing of Non-steroidal Anti-inflammatory Drugs in Patients With Osteoarthritis–an Expert Consensus Addressing Benefits as Well as Gastrointestinal and Cardiovascular Risks,” BMC Medicine [Electronic Resource] 13 (2015): 55.

[65] D. Heinegård and T. Saxne, “The Role of the Cartilage Matrix in Osteoarthritis,” Nature Reviews Rheumatology 7, no. 1 (2010): 50–56.

[66] R. F. Loeser, S. R. Goldring, C. R. Scanzello, and M. B. Goldring, “Osteoarthritis: A Disease of the Joint as an Organ,” Arthritis & Rheumatism 64, no. 6 (2012): 1697–1707.

[67] X. Fan, X. Wu, R. Crawford, Y. Xiao, and I. Prasadam, “Macro, Micro, and Molecular. Changes of the Osteochondral Interface in Osteoarthritis Development,” Frontiers in Cell and Developmental Biology 9 (2021): 659654.

[68] S. Chawla, A. Mainardi, N. Majumder, et al., “Chondrocyte Hypertrophy in Osteoarthritis: Mechanistic Studies and Models for the Identification of New Therapeutic Strategies,” Cells 11, no. 24 (2022): 4034.

[69] Y. A. Rim, Y. Nam, and J. H. Ju, “The Role of Chondrocyte Hypertrophy and Senescence in Osteoarthritis Initiation and Progression,” International Journal of Molecular Sciences 21, no. 7 (2020): 2358.

[70] C. Lian, X. Wang, X. Qiu, et al., “Collagen Type II Suppresses Articular Chondrocyte Hypertrophy and Osteoarthritis Progression by Promoting Integrin β1−SMAD1 Interaction,” Bone Research 7 (2019): 8.

[71] Y. Liu, Z. Zhang, T. Li, H. Xu, and H. Zhang, “Senescence in Osteoarthritis: From Mechanism to Potential Treatment,” Arthritis Research & Therapy 24, no. 1 (2022): 174.

[72] H. Yuan, N. Yi, D. Li, et al., “PPARgamma Regulates Osteoarthritis Chondrocytes Apoptosis Through Caspase-3 Dependent Mitochondrial Pathway,” Scientific Reports 14, no. 1 (2024): 11237.

[73] Z. Zhao, X. Sun, P. Tu, et al., “Mechanisms of Vascular Invasion After Cartilage Injury and Potential Engineering Cartilage Treatment Strategies,” Faseb Journal 38, no. 6 (2024): e23559.

[74] W. Hu, Y. Chen, C. Dou, and S. Dong, “Microenvironment in Subchondral Bone: Predominant Regulator for the Treatment of Osteoarthritis,” Annals of the Rheumatic Diseases 80, no. 4 (2021): 413–422.

[75] Y. Yang, P. Li, S. Zhu, and R. Bi, “Comparison of Early-stage Changes of Osteoarthritis in Cartilage and Subchondral Bone Between Two Different Rat Models,” PeerJ 8 (2020): e8934.

[76] P. I. Mapp and D. A. Walsh, Nature Reviews Rheumatology 8, no. 7 (2012): 390–398.

[77] S. Donell, “Subchondral Bone Remodelling in Osteoarthritis,” EFORT Open Reviews 4, no. 6 (2019): 221–229.

[78] Y. Hu, X. Chen, S. Wang, Y. Jing, and J. Su, “Subchondral Bone Microenvironment in Osteoarthritis and Pain,” Bone Research 9, no. 1 (2021): 20.

[79] I. Ilia, D. Nitusca, and C. Marian, “Adiponectin in Osteoarthritis: Pathophysiology, Relationship With Obesity and Presumptive Diagnostic Biomarker Potential,” Diagnostics (Basel) 12, no. 2 (2022): 455.

[80] K. Wang, J. Xu, J. Cai, et al., “Serum Levels of Interleukin-17 and Adiponectin Are Associated With Infrapatellar Fat Pad Volume and Signal Intensity Alteration in Patients With Knee Osteoarthritis,” Arthritis Research & Therapy 18, no. 1 (2016): 193.

[81] E. Belluzzi, V. Macchi, C. G. Fontanella, et al., “Infrapatellar Fat Pad Gene Expression and Protein Production in Patients With and Without Osteoarthritis,” International Journal of Molecular Sciences 21, no. 17 (2020): 6016.

[82] B. Pereira Herrera, K. Emanuel, P. J. Emans, M. van Griensven, and B. Cillero-Pastor, “Infrapatellar Fat Pad as a Source of Biomarkers and Therapeutic Target for Knee Osteoarthritis,” Arthritis Research & Therapy 27, no. 1 (2025): 81.

[83] S. Silawal, J. Triebel, T. Bertsch, and G. Schulze-Tanzil, “Osteoarthritis and the Complement Cascade,” Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders 11 (2018): 1179544117751430.

[84] H. Peters, P. Potla, J. S. Rockel, et al., “Cell and Transcriptomic Diversity of Infrapatellar Fat Pad During Knee Osteoarthritis,” Annals of the Rheumatic Diseases 84, no. 2 (2025): 351–367.

[85] L. Dudaric, I. Dumic-Cule, E. Divjak, T. Cengic, B. Brkljacic, and G. Ivanac, “Bone Remodeling in Osteoarthritis-Biological and Radiological Aspects,” Medicina (Kaunas, Lithuania) 59, no. 9 (2023): 1613.

[86] W. Su, G. Liu, X. Liu, et al., “Angiogenesis Stimulated by Elevated PDGF-BB in Subchondral Bone Contributes to Osteoarthritis Development,” JCI Insight 5, no. 8 (2020): e135446.

[87] Z. Cui, H. Wu, Y. Xiao, et al., “Endothelial PDGF-BB/PDGFR-β Signaling Promotes Osteoarthritis by Enhancing Angiogenesis-dependent Abnormal Subchondral Bone Formation,” Bone Research 10, no. 1 (2022): 58.

[88] Y. A. Pei, S. Chen, and M. Pei, “The Essential Anti-angiogenic Strategies in Cartilage Engineering and Osteoarthritic Cartilage Repair,” Cellular and Molecular Life Sciences 79, no. 1 (2022): 71.

[89] S. Grässel and D. Muschter, “Peripheral Nerve Fibers and Their Neurotransmitters in Osteoarthritis Pathology,” International Journal of Molecular Sciences 18, no. 5 (2017): 931.

[90] S. Stöckl, A. Eitner, R. J. Bauer, M. König, B. Johnstone, and S. Grässel, “Substance P and Alpha-Calcitonin Gene-Related Peptide Differentially Affect Human Osteoarthritic and Healthy Chondrocytes,” Frontiers in Immunology 12 (2021): 722884.

[91] S. Zhu, J. Zhu, G. Zhen, et al., “Subchondral Bone Osteoclasts Induce Sensory Innervation and Osteoarthritis Pain,” Journal of Clinical Investigation 129, no. 3 (2019): 1076–1093.

[92] J. Zhu, G. Zhen, S. An, et al., “Aberrant Subchondral Osteoblastic Metabolism Modifies Na(V)1.8 for Osteoarthritis,” Elife 9 (2020): e57656.

[93] H. Zhang, L. Wang, J. Cui, et al., “Maintaining Hypoxia Environment of Subchondral Bone Alleviates Osteoarthritis Progression,” Science Advances 9, no. 14 (2023): eabo7868.

[94] K. Aso, D. A. Walsh, H. Wada, et al., “Time Course and Localization of Nerve Growth Factor Expression and Sensory Nerve Growth During Progression of Knee Osteoarthritis in Rats,” Osteoarthritis and Cartilage 30, no. 10 (2022): 1344–1355.

[95] W. A. Batarfi, M. H. M. Yunus, A. A. Hamid, M. Maarof, and R. Abdul Rani, “Breaking down Osteoarthritis: Exploring Inflammatory and Mechanical Signaling Pathways,” Life (Basel) 15, no. 8 (2025): 1238.

[96] V. Ulivi, P. Giannoni, C. Gentili, R. Cancedda, and F. Descalzi, “p38/NF-kB-dependent Expression of COX-2 During Differentiation and Inflammatory Response of Chondrocytes,” Journal of Cellular Biochemistry 104, no. 4 (2008): 1393–1406.

[97] T. Saito, A. Fukai, A. Mabuchi, et al., “Transcriptional Regulation of Endochondral Ossification by HIF-2alpha During Skeletal Growth and Osteoarthritis Development,” Nature Medicine 16, no. 6 (2010): 678–686.

[98] D. Chen, D. J. Kim, J. Shen, Z. Zou, and R. J. O'Keefe, “Runx2 plays a central Role in Osteoarthritis Development,” Journal of Orthopaedic Translation 23 (2020): 132–139.

[99] F. Wang, Z. Guo, and Y. Yuan, “STAT3 speeds up Progression of Osteoarthritis Through NF-κB Signaling Pathway,” Experimental and Therapeutic Medicine 19, no. 1 (2020): 722–728.

[100] Q. Zhou, Q. Ren, L. Jiao, et al., “The Potential Roles of JAK/STAT Signaling in the Progression of Osteoarthritis,” Frontiers in Endocrinology (Lausanne) 13 (2022): 1069057.

[101] M. Xu, X. Chen, S. Du, H. Xu, and C. Liu, “Isoginkgetin Protects Chondrocytes and Inhibits Osteoarthritis Through NF-κB and P21 Signaling Pathway,” Molecular Medicine 31, no. 1 (2025): 246.

[102] H. Zhuang, X. Ren, F. Jiang, and P. Zhou, “Indole-3-propionic Acid Alleviates Chondrocytes Inflammation and Osteoarthritis via the AhR/NF-κB Axis,” Molecular Medicine 29, no. 1 (2023): 17.

[103] W. Xia, J. Xiao, C. Tong, et al., “Orientin Inhibits Inflammation in Chondrocytes and Attenuates Osteoarthritis Through Nrf2/NF-κB and SIRT6/NF-κB Pathway,” Journal of Orthopaedic Research 41, no. 11 (2023): 2405–2417.

[104] D. Jiang, X. Xu, W. Yang, et al., “Neuregulin 4 Inhibits Synovial Macrophage Pro-inflammatory Polarization via ErbB4/Stat5b/NF-κB Signaling to Alleviate Osteoarthritis Progression,” Journal of Orthopaedic Surgery and Research 20, no. 1 (2025): 835.

[105] C. N. Lan, W. J. Cai, J. Shi, and Z. J. Yi, “MAPK Inhibitors Protect Against Early‑Stage Osteoarthritis by Activating Autophagy,” Molecular Medicine Reports 24, no. 6 (2021): 829.

[106] F. Wang, J. Xiao, M. Li, et al., “Picroside II Suppresses Chondrocyte Pyroptosis Through MAPK/NF-κB/NLRP3 Signaling Pathway Alleviates Osteoarthritis,” PLoS ONE 19, no. 8 (2024): e0308731.

[107] H. Sun, Z. Li, N. Liu, et al., “Long Non-coding RNA SNHG7 Suppresses Inflammation and Apoptosis of Chondrocytes through Inactivating of p38 MAPK Signaling Pathway in Osteoarthritis,” Molecular Biotechnology 66, no. 9 (2024): 2287–2296.

[108] L. Jie, Y. Zhang, J. Liu, et al., “PINK1 overexpression Suppresses p38 MAPK/NF‑κB Signaling to Attenuate Chondrocyte Senescence in Osteoarthritis,” International Journal of Molecular Medicine 56, no. 6 (2025): 224.

[109] X. Jin, X. Wang, S. Xu, et al., “Growth Factor Independence 1 Ameliorates Osteoarthritis by Inhibiting Chondrocyte Ferroptosis via Inactivation of MAPK Signaling Pathway,” Journal of Orthopaedic Translation 54 (2025): 101–114.

[110] Y. Y. Chen, Y. Chen, W. C. Wang, et al., “Cyclin D1 Regulates Osteoarthritis Chondrocyte Apoptosis via WNT3/β-catenin Signalling,” Artificial Cells, Nanomedicine, and Biotechnology 47, no. 1 (2019): 1971–1977.

[111] Y. Usami, A. T. Gunawardena, M. Iwamoto, and M. Enomoto-Iwamoto, “Wnt Signaling in Cartilage Development and Diseases: Lessons From Animal Studies,” Laboratory Investigation 96, no. 2 (2016): 186–196.

[112] A. J. Knights, E. C. Farrell, O. M. Ellis, et al., “Synovial Fibroblasts Assume Distinct Functional Identities and Secrete R-spondin 2 in Osteoarthritis,” Annals of the Rheumatic Diseases 82, no. 2 (2023): 272–282.

[113] G. Nalesso, B. L. Thomas, J. C. Sherwood, et al., “WNT16 antagonises Excessive Canonical WNT Activation and Protects Cartilage in Osteoarthritis,” Annals of the Rheumatic Diseases 76, no. 1 (2017): 218–226.

[114] W. Tong, Y. Zeng, D. H. K. Chow, et al., “Wnt16 attenuates Osteoarthritis Progression Through a PCP/JNK-mTORC1-PTHrP Cascade,” Annals of the Rheumatic Diseases 78, no. 4 (2019): 551–561.

[115] A. L. Gibson, C. K. Hui Mingalone, A. T. Foote, T. Uchimura, M. Zhang, and L. Zeng, “Wnt7a Inhibits IL-1β Induced Catabolic Gene Expression and Prevents Articular Cartilage Damage in Experimental Osteoarthritis,” Scientific Reports 7 (2017): 41823.

[116] G. Huang, S. Chubinskaya, W. Liao, and R. F. Loeser, “Wnt5a induces Catabolic Signaling and Matrix Metalloproteinase Production in human Articular Chondrocytes,” Osteoarthritis and Cartilage 25, no. 9 (2017): 1505–1515.

[117] S. Shi, Z. Man, and S. Sun, “Wnt3a knockdown Promotes Collagen Type II Expression in Rat Chondrocytes,” Experimental and Therapeutic Medicine 24, no. 2 (2022): 526.

[118] C. G. Boer, M. S. Yau, S. J. Rice, et al., “Genome-wide Association of Phenotypes Based on Clustering Patterns of Hand Osteoarthritis Identify WNT9A as Novel Osteoarthritis Gene,” Annals of the Rheumatic Diseases 80, no. 3 (2021): 367–375.

[119] S. Teufel, L. Wolff, U. König, A. Kobayashi, R. Behringer, and C. Hartmann, “Mice Lacking Wnt9a or Wnt4 Are Prone to Develop Spontaneous Osteoarthritis with Age and Display Alteration in either the Trabecular or Cortical Bone Compartment,” Journal of Bone and Mineral Research 37, no. 7 (2022): 1335–1351.

[120] W. S. Lian, R. W. Wu, J. Y. Ko, et al., “Inhibition of Histone Lysine Demethylase 6A Promotes Chondrocytic Activity and Attenuates Osteoarthritis Development Through Repressing H3K27me3 Enhancement of Wnt10a,” International Journal of Biochemistry & Cell Biology 158 (2023): 106394.

[121] A. Escribano-Núñez, F. M. F. Cornelis, A. De Roover, et al., “IGF1 drives Wnt-induced Joint Damage and Is a Potential Therapeutic Target for Osteoarthritis,” Nature Communications 15, no. 1 (2024): 9170.

[122] K. Lu, Z. Liao, J. Li, et al., “MSAB Limits Osteoarthritis Development and Progression Through Inhibition of β-catenin-DDR2 Signaling,” Bioactive Materials 46 (2025): 259–272.

[123] Y. Wang, X. Fan, L. Xing, and F. Tian, “Wnt Signaling: A Promising Target for Osteoarthritis Therapy,” Cell Communication and Signaling 17, no. 1 (2019): 97.

[124] C. Lietman, B. Wu, S. Lechner, et al., “Inhibition of Wnt/β-catenin Signaling Ameliorates Osteoarthritis in a Murine Model of Experimental Osteoarthritis,” JCI Insight 3, no. 3 (2018): e96308.

[125] A. K. Gill, P. J. McCormick, D. Sochart, and G. Nalesso, “Wnt Signalling in the Articular Cartilage: A Matter of Balance,” International Journal of Experimental Pathology 104, no. 2 (2023): 56–63.

[126] J. Cheng, M. Li, and R. Bai, “The Wnt Signaling Cascade in the Pathogenesis of Osteoarthritis and Related Promising Treatment Strategies,” Frontiers in Physiology 13 (2022): 954454.

[127] X. Li, Y. Han, G. Li, Y. Zhang, J. Wang, and C. Feng, “Role of Wnt Signaling Pathway in Joint Development and Cartilage Degeneration,” Frontiers in Cell and Developmental Biology 11 (2023): 1181619.

[128] K. Sun, J. Luo, J. Guo, X. Yao, X. Jing, and F. Guo, “The PI3K/AKT/mTOR Signaling Pathway in Osteoarthritis: A Narrative Review,” Osteoarthritis and Cartilage 28, no. 4 (2020): 400–409.

[129] R. Zhang, X. Deng, Q. Liu, et al., “Global Research Trends and Hotspots of PI3K/Akt Signaling Pathway in the Field of Osteoarthritis: A Bibliometric Study,” Medicine 102, no. 15 (2023): e33489.

[130] X. Pan, H. Shan, J. Bai, et al., “Four-octyl Itaconate Improves Osteoarthritis by Enhancing Autophagy in Chondrocytes via PI3K/AKT/mTOR Signalling Pathway Inhibition,” Communications Biology 5, no. 1 (2022): 641.

[131] Y. Chen, X. Pan, J. Zhao, et al., “Icariin Alleviates Osteoarthritis Through PI3K/Akt/mTOR/ULK1 Signaling Pathway,” European Journal of Medical Research 27, no. 1 (2022): 204.

[132] K. Xu, Y. He, S. A. A. Moqbel, X. Zhou, L. Wu, and J. Bao, “SIRT3 ameliorates Osteoarthritis via Regulating Chondrocyte Autophagy and Apoptosis Through the PI3K/Akt/mTOR Pathway,” International Journal of Biological Macromolecules 175 (2021): 351–360.

[133] T. Xu, K. Liu, J. Fan, et al., “Metformin Mitigates Osteoarthritis Progression by Modulating the PI3K/AKT/mTOR Signaling Pathway and Enhancing Chondrocyte Autophagy,” Open Life Sciences 19, no. 1 (2024): 20220922.

[134] D. Zhao, J. Nong, X. Li, et al., “Perillyl Alcohol Promotes Autophagy by Suppressing the PI3K-AKT-mTOR Signalling Pathway in Osteoarthritic Chondrocytes in Vitro,” Scientific Reports 15, no. 1 (2025): 26549.

[135] J. Li, F. Sun, Y. Zhang, et al., “MiR-103-3p Regulates Chondrocyte Autophagy, Apoptosis, and ECM Degradation Through the PI3K/Akt/mTOR Pathway by Targeting CPEB3,” Journal of Orthopaedic Surgery and Research 20, no. 1 (2025): 324.

[136] Z. Wang, H. Xu, Z. Wang, et al., “Traditional Chinese Manual Therapy (Tuina) Improves Knee Osteoarthritis by Regulating Chondrocyte Autophagy and Apoptosis via the PI3K/AKT/mTOR Pathway: An in Vivo Rat Experiment and Machine Learning Study,” Journal of Inflammation Research 17 (2024): 6501–6519.

[137] L. Cheng, S. Chang, Y. Tan, and B. He, “Platelet-rich Plasma Combined With Isometric Quadriceps Contraction Regulates Autophagy in Chondrocytes via the PI3K/AKT/mTOR Pathway to Promote Cartilage Repair in Knee Osteoarthritis,” Regenerative Therapy 28 (2025): 81–89.

[138] J. F. Xue, Z. M. Shi, J. Zou, and X. L. Li, “Inhibition of PI3K/AKT/mTOR Signaling Pathway Promotes Autophagy of Articular Chondrocytes and Attenuates Inflammatory Response in Rats With Osteoarthritis,” Biomedicine & Pharmacotherapy 89 (2017): 1252–1261.

[139] W. Yao, X. Hu, and X. Wang, “Crossing Epigenetic Frontiers: The Intersection of Novel Histone Modifications and Diseases,” Signal Transduction and Targeted Therapy 9, no. 1 (2024): 232.

[140] G. Millán-Zambrano, A. Burton, A. J. Bannister, and R. Schneider, “Histone Post-translational Modifications—cause and Consequence of Genome Function,” Nature Reviews Genetics 23, no. 9 (2022): 563–580.

[141] L. D. Moore, T. Le, and G. Fan, “DNA Methylation and Its Basic Function,” Neuropsychopharmacology 38, no. 1 (2013): 23–38.

[142] K. Günther, M. Rust, J. Leers, et al., “Differential Roles for MBD2 and MBD3 at Methylated CpG Islands, Active Promoters and Binding to Exon Sequences,” Nucleic Acids Research 41, no. 5 (2013): 3010–3021.

[143] W. Wang, Y. Yu, J. Hao, et al., “Genome-wide DNA Methylation Profiling of Articular Cartilage Reveals Significant Epigenetic Alterations in Kashin-Beck Disease and Osteoarthritis,” Osteoarthritis and Cartilage 25, no. 12 (2017): 2127–2133.

[144] E. McDonnell, S. E. Orr, M. J. Barter, et al., “The Methylomic Landscape of human Articular Cartilage Development Contains Epigenetic Signatures of Osteoarthritis Risk,” American Journal of Human Genetics 111, no. 12 (2024): 2756–2772.

[145] E. McDonnell, S. E. Orr, M. J. Barter, et al., “Epigenetic Mechanisms of Osteoarthritis Risk in human Skeletal Development,” medRxiv (2024), [Preprint], 2024.05.05.24306832.

[146] Y. Zhang, N. Fukui, M. Yahata, et al., “Genome-wide DNA Methylation Profile Implicates Potential Cartilage Regeneration at the Late Stage of Knee Osteoarthritis,” Osteoarthritis and Cartilage 24, no. 5 (2016): 835–843.

[147] L. N. Reynard, C. Bui, E. G. Canty-Laird, D. A. Young, and J. Loughlin, “Expression of the Osteoarthritis-associated Gene GDF5 Is Modulated Epigenetically by DNA Methylation,” Human Molecular Genetics 20, no. 17 (2011): 3450–3460.

[148] K. Kania, F. Colella, A. H. K. Riemen, et al., “Regulation of Gdf5 Expression in Joint Remodelling, Repair and Osteoarthritis,” Scientific Reports 10, no. 1 (2020): 157.

[149] P. Smeriglio, F. C. Grandi, S. Davala, et al., “Inhibition of TET1 Prevents the Development of Osteoarthritis and Reveals the 5hmC Landscape That Orchestrates Pathogenesis,” Science Translational Medicine 12, no. 539 (2020): eaax2332.

[150] P. Renpeng, M. Zheng, H. Kang, et al., “Methyl-CpG-binding Domain 2 Mitigates Osteoarthritis Through Steap3 Promoter Methylation and Chondrocyte Ferroptosis Regulation,” Experimental & Molecular Medicine 57, no. 11 (2025): 2629–2642.

[151] Y. Kawarai, J. Nakamura, S. Hagiwara, M. Suzuki-Narita, K. Inage, and S. Ohtori, “Alterations in DNA Methylation Machinery in a Rat Model of Osteoarthritis of the Hip,” Journal of Orthopaedic Surgery and Research 19, no. 1 (2024): 357.

[152] C. M. Dunn, C. Sturdy, C. Velasco, et al., “Peripheral Blood DNA Methylation-Based Machine Learning Models for Prediction of Knee Osteoarthritis Progression: Biologic Specimens and Data from the Osteoarthritis Initiative and Johnston County Osteoarthritis Project,” Arthritis & Rheumatology 75, no. 1 (2023): 28–40.

[153] S. J. Yi, H. Lee, J. Lee, et al., “Bone Remodeling: Histone Modifications as Fate Determinants of Bone Cell Differentiation,” International Journal of Molecular Sciences 20, no. 13 (2019): 3147.

[154] P. Sun, T. Huang, C. Huang, Y. Wang, and D. Tang, “Role of Histone Modification in the Occurrence and Development of Osteoporosis,” Frontiers in Endocrinology (Lausanne) 13 (2022): 964103.

[155] L. Morera, M. Lübbert, and M. Jung, “Targeting Histone Methyltransferases and Demethylases in Clinical Trials for Cancer Therapy,” Clinical Epigenetics 8 (2016): 57.

[156] J. C. Black, C. Van Rechem, and J. R. Whetstine, “Histone Lysine Methylation Dynamics: Establishment, Regulation, and Biological Impact,” Molecular Cell 48, no. 4 (2012): 491–507.

[157] K. Hyun, J. Jeon, K. Park, and J. Kim, “Writing, Erasing and Reading Histone Lysine Methylations,” Experimental & Molecular Medicine 49, no. 4 (2017): e324.

[158] E. Guccione and S. Richard, “The Regulation, Functions and Clinical Relevance of Arginine Methylation,” Nature Reviews Molecular Cell Biology 20, no. 10 (2019): 642–657.

[159] B. Perillo, A. Tramontano, A. Pezone, and A. Migliaccio, “LSD1: More Than Demethylation of Histone Lysine Residues,” Experimental & Molecular Medicine 52, no. 12 (2020): 1936–1947.

[160] L. Zhang, Y. Chen, Z. Li, C. Lin, T. Zhang, and G. Wang, “Development of JmjC-domain-containing Histone Demethylase (KDM2-7) Inhibitors for Cancer Therapy,” Drug Discovery Today 28, no. 5 (2023): 103519.

[161] T. Ito, N. Yadav, J. Lee, et al., “Arginine Methyltransferase CARM1/PRMT4 Regulates Endochondral Ossification,” BMC Developmental Biology 9 (2009): 47.

[162] M. Sun, S. Hussain, Y. Hu, et al., “Maintenance of SOX9 Stability and ECM Homeostasis by Selenium-sensitive PRMT5 in Cartilage,” Osteoarthritis and Cartilage 27, no. 6 (2019): 932–944.

[163] J. O. SY, M. S. Domowicz, J. G. Henry, and N. B. Schwartz, “The Role of Dot1l in Prenatal and Postnatal Murine Chondrocytes and Trabecular Bone,” JBMR Plus 4, no. 2 (2019): e10254.

[164] M. C. Castaño Betancourt, F. Cailotto, H. J. Kerkhof, et al., “Genome-wide Association and Functional Studies Identify the DOT1L Gene to be Involved in Cartilage Thickness and Hip Osteoarthritis,” Proceedings of the National Academy of Sciences of the United States of America 109, no. 21 (2012): 8218–8223.

[165] A. De Roover, A. E. Núñez, F. M. Cornelis, et al., “Hypoxia Induces DOT1L in Articular Cartilage to Protect Against Osteoarthritis,” JCI Insight 6, no. 24 (2021): e150451.

[166] E. T. Camilleri, A. Dudakovic, S. M. Riester, et al., “Loss of Histone Methyltransferase Ezh2 Stimulates an Osteogenic Transcriptional Program in Chondrocytes but Does Not Affect Cartilage Development,” Journal of Biological Chemistry 293, no. 49 (2018): 19001–19011.

[167] F. Liu, D. Y. Song, J. Huang, H. Q. Yang, D. You, and J. D. Ni, “Long Non-coding RNA CIR Inhibits Chondrogenic Differentiation of Mesenchymal Stem Cells by Epigenetically Suppressing ATOH8 via Methyltransferase EZH2,” Molecular Medicine 27, no. 1 (2021): 12.

[168] K. A. Lawson, C. J. Teteak, J. Zou, et al., “Mesenchyme-specific Knockout of ESET Histone Methyltransferase Causes Ectopic Hypertrophy and Terminal Differentiation of Articular Chondrocytes,” Journal of Biological Chemistry 288, no. 45 (2013): 32119–32125.

[169] R. Shao, J. Suo, Z. Zhang, et al., “H3K36 methyltransferase NSD1 Protects Against Osteoarthritis Through Regulating Chondrocyte Differentiation and Cartilage Homeostasis,” Cell Death and Differentiation 31, no. 1 (2024): 106–118.

[170] A. L. Durand, A. Dufour, and E. Aubert-Foucher, “The Lysine Specific Demethylase-1 Negatively Regulates the COL9A1 Gene in Human Articular Chondrocytes,” International Journal of Molecular Sciences 21, no. 17 (2020): 6322.

[171] M. Rodova, Q. Lu, Y. Li, et al., “Nfat1 regulates Adult Articular Chondrocyte Function Through Its Age-dependent Expression Mediated by Epigenetic Histone Methylation,” Journal of Bone and Mineral Research 26, no. 8 (2011): 1974–1986.

[172] Y. Fu, S. Yi, Q. Peng, H. Jiang, and J. Zhou, “KDM3A Modulates Biological Processes in Osteoarthritis Cell Models via the Wnt/β-Catenin Signaling Pathway,” Cartilage (2025): 19476035251344878, https://doi.org/10.1177/19476035251344878.

[173] H. L. Lee, B. Yu, P. Deng, C. Y. Wang, and C. Hong, “Transforming Growth Factor-β-Induced KDM4B Promotes Chondrogenic Differentiation of Human Mesenchymal Stem Cells,” Stem Cells 34, no. 3 (2016): 711–719.

[174] K. Chen, H. Fang, and N. Xu, “LncRNA LOXL1-AS1 Is Transcriptionally Activated by JUND and Contributes to Osteoarthritis Progression via Targeting the miR-423-5p/KDM5C Axis,” Life Sciences 258 (2020): 118095.

[175] Z. Zhi, C. Zhang, J. Kang, et al., “The Therapeutic Effect of Bone Marrow-derived Mesenchymal Stem Cells on Osteoarthritis Is Improved by the Activation of the KDM6A/SOX9 Signaling Pathway Caused by Exposure to Hypoxia,” Journal of Cellular Physiology 235, no. 10 (2020): 7173–7182.

[176] H. Liao, Q. Tu, Y. Kang, et al., “CircNFIX Regulates Chondrogenesis and Cartilage Homeostasis by Targeting the miR758-3p/KDM6A Axis,” Cell Proliferation 55, no. 11 (2022): e13302.

[177] J. Dai, D. Yu, Y. Wang, et al., “Kdm6b regulates Cartilage Development and Homeostasis Through Anabolic Metabolism,” Annals of the Rheumatic Diseases 76, no. 7 (2017): 1295–1303.

[178] H. Du, Y. Zhang, X. Yu, et al., “Inhibition of KDM6B Prevents Osteoarthritis by Blocking Growth Plate-Like H3K27me3 Loss in Bivalent Genes,” Science China Life Sciences 68, no. 5 (2025): 1423–1436.

[179] Q. Shen, Y. Xiao, B. Cheng, et al., “PRMT1 promotes Extracellular Matrix Degradation and Apoptosis of Chondrocytes in Temporomandibular Joint Osteoarthritis via the AKT/FOXO1 Signaling Pathway,” International Journal of Biochemistry & Cell Biology 141 (2021): 106112.

[180] S. Tang, Y. Cao, Z. Cai, et al., “The lncRNA PILA Promotes NF-κB Signaling in Osteoarthritis by Stimulating the Activity of the Protein Arginine Methyltransferase PRMT1,” Science Signaling 15, no. 735 (2022): eabm6265.

[181] L. Xia, H. X. Zhang, M. L. Xing, et al., “Knockdown of PRMT1 Suppresses IL-1beta-induced Cartilage Degradation and Inflammatory Responses in human Chondrocytes Through Gli1-mediated Hedgehog Signaling Pathway,” Molecular and Cellular Biochemistry 438, no. 1-2 (2018): 17–24.

[182] Y. Dong, P. Wang, Y. Yang, et al., “PRMT5 inhibition Attenuates Cartilage Degradation by Reducing MAPK and NF-kappaB Signaling,” Arthritis Research & Therapy 22, no. 1 (2020): 201.

[183] L. Allas, S. Brochard, Q. Rochoux, et al., “EZH2 inhibition Reduces Cartilage Loss and Functional Impairment Related to Osteoarthritis,” Scientific Reports 10, no. 1 (2020): 19577.

[184] F. E. El Mansouri, N. Chabane, and N. Zayed, “Contribution of H3K4 Methylation by SET-1A to Interleukin-1-induced Cyclooxygenase 2 and Inducible Nitric Oxide Synthase Expression in human Osteoarthritis Chondrocytes,” Arthritis and Rheumatism 63, no. 1 (2011): 168–179.

[185] Z. Luobu, L. Wang, D. Jiang, T. Liao, C. Luobu, and L. Qunpei, “CircSCAPER Contributes to IL-1-induced Osteoarthritis in Vitro via miR-140-3p/EZH2 Axis,” Bone & Joint Research 11, no. 2 (2022): 61–72.

[186] X. Du, Y. Chen, Q. Zhang, et al., “Ezh2 Ameliorates Osteoarthritis by Activating TNFSF13B,” Journal of Bone and Mineral Research 35, no. 5 (2020): 956–965.

[187] F. E. El Mansouri, S. S. Nebbaki, M. Kapoor, et al., “Lysine-specific Demethylase 1-mediated Demethylation of Histone H3 Lysine 9 Contributes to Interleukin 1β-induced Microsomal Prostaglandin E Synthase 1 Expression in human Osteoarthritic Chondrocytes,” Arthritis Research & Therapy 16, no. 3 (2014): R113.

[188] Y. Huang, W. Pan, and J. Ma, “SKP2-mediated Ubiquitination and Degradation of KLF11 Promotes Osteoarthritis via Modulation of JMJD3/NOTCH1 Pathway,” Faseb Journal 38, no. 9 (2024): e23640.

[189] Y. Jin, Z. Liu, Z. Li, et al., “Histone Demethylase JMJD3 Downregulation Protects Against Aberrant Force-induced Osteoarthritis Through Epigenetic Control of NR4A1,” International Journal of Oral Science 14, no. 1 (2022): 34.

[190] F. Yang, S. Zhou, C. Wang, et al., “Epigenetic Modifications of Interleukin-6 in Synovial Fibroblasts From Osteoarthritis Patients,” Scientific Reports 7 (2017): 43592.

[191] T. Wang and C. He, “Pro-inflammatory Cytokines: The Link Between Obesity and Osteoarthritis,” Cytokine & Growth Factor Reviews 44 (2018): 38–50.

[192] M. Trenkmann, M. Brock, R. E. Gay, et al., “Expression and Function of EZH2 in Synovial Fibroblasts: Epigenetic Repression of the Wnt Inhibitor SFRP1 in Rheumatoid Arthritis,” Annals of the Rheumatic Diseases 70, no. 8 (2011): 1482–1488.

[193] M. Frank-Bertoncelj, M. Trenkmann, K. Klein, et al., “Epigenetically-driven Anatomical Diversity of Synovial Fibroblasts Guides Joint-specific Fibroblast Functions,” Nature Communications 8 (2017): 14852.

[194] K. Wang, F. Li, Y. Yuan, et al., “Synovial Mesenchymal Stem Cell-Derived EV-Packaged miR-31 Downregulates Histone Demethylase KDM2A to Prevent Knee Osteoarthritis,” Molecular Therapy—Nucleic Acids 22 (2020): 1078–1091.

[195] R. Wang, B. Mehrjou, D. Dehghan-Banian, et al., “Targeting Long Noncoding RNA H19 in Subchondral Bone Osteocytes and the Alleviation of Cartilage Degradation in Osteoarthritis,” Arthritis & Rheumatology 77, no. 3 (2025): 283–297.

[196] K. Doi, K. Murata, S. Ito, et al., “Role of Lysine-Specific Demethylase 1 in Metabolically Integrating Osteoclast Differentiation and Inflammatory Bone Resorption through Hypoxia-Inducible Factor 1α and E2F1,” Arthritis & Rheumatology 74, no. 6 (2022): 948–960.

[197] G. Zhang, Y. Zhou, M. Su, X. Yang, and B. Zeng, “Inhibition of microRNA-27b-3p Relieves Osteoarthritis Pain via Regulation of KDM4B-dependent DLX5,” Biofactors 46, no. 5 (2020): 788–802.

[198] R. Wang, D. Shi, X. Pan, A. Ren, and K. Jiang, “Epigenetic Mechanisms of Nsd1-mediated Histone Methylation Modifications in Chondrocyte Ferroptosis in Knee Osteoarthritis,” Biomolecules and Biomedicine 25, no. 4 (2025): 894–904.

[199] P. Yu, X. Zhang, N. Liu, L. Tang, C. Peng, and X. Chen, “Pyroptosis: Mechanisms and Diseases,” Signal Transduction and Targeted Therapy 6, no. 1 (2021): 128.

[200] Y. Chen, S. Dong, X. Zeng, et al., “EZH2/miR-142-3p/HMGB1 Axis Mediates Chondrocyte Pyroptosis by Regulating Endoplasmic Reticulum Stress in Knee Osteoarthritis,” Chinese Medical Journal 138, no. 1 (2024): 79–92.

[201] H. Jeon and G. I. Im, “Autophagy in Osteoarthritis,” Connective Tissue Research 58, no. 6 (2017): 497–508.

[202] W.-S. Lian, J.-Y. Ko, R.-W. Wu, et al., “MicroRNA-128a Represses Chondrocyte Autophagy and Exacerbates Knee Osteoarthritis by Disrupting Atg12,” Cell Death & Disease 9, no. 9 (2018): 919.

[203] S. Liu, S. Yao, H. Yang, S. Liu, and Y. Wang, “Autophagy: Regulator of Cell Death,” Cell Death & Disease 14, no. 10 (2023): 648.

[204] Y. Jin, Z. Li, Y. Wu, et al., “Aberrant Fluid Shear Stress Contributes to Articular Cartilage Pathogenesis via Epigenetic Regulation of ZBTB20 by H3K4me3,” Journal of Inflammation Research 14 (2021): 6067–6083.

[205] C. Wang and R. Zhang, “The Effect of ITLN1, XCL2 and DOT1L Variants on Knee Osteoarthritis Risk in the Han Population,” Archives of Orthopaedic and Trauma Surgery 143, no. 8 (2023): 4821–4831.

[206] Y.-R. Choi, K. H. Collins, J.-W. Lee, H.-J. Kang, and F. Guilak, “Genome Engineering for Osteoarthritis: From Designer Cells to Disease-Modifying Drugs,” Tissue Engineering and Regenerative Medicine 16, no. 4 (2019): 335–343.

[207] W. S. Lian, R. W. Wu, J. Y. Ko, et al., “Histone H3K27 Demethylase UTX Compromises Articular Chondrocyte Anabolism and Aggravates Osteoarthritic Degeneration,” Cell Death & Disease 13, no. 6 (2022): 538.

[208] J. Xiaoshi, L. Maoquan, W. Jiwei, N. Jinqiu, and Z. Ke, “SETD7 mediates the Vascular Invasion in Articular Cartilage and Chondrocytes Apoptosis in Osteoarthriis,” Faseb Journal 35, no. 3 (2021): e21283.

[209] X. Liu, P. Zhang, Y. Gu, Q. Guo, and Y. Liu, “Type H Vessels: Functions in Bone Development and Diseases,” Frontiers in Cell and Developmental Biology 11 (2023): 1236545.

[210] J. Y. Wang and A. Q. Lu, “The Biological Function of m6A Reader YTHDF2 and Its Role in human Disease,” Cancer Cell International 21, no. 1 (2021): 109.

[211] S. Xiao, S. Duan, M. A. Caligiuri, S. Ma, and J. Yu, “YTHDF2: A Key RNA Reader and Antitumor Target,” Trends in Immunology 46, no. 6 (2025): 485–498.

[212] L. Li, J. Zhu, Y. Chen, et al., “Interaction between YTH Domain-Containing Family Protein 2 and SET Domain-Containing Lysine Methyltransferase 7 Suppresses Autophagy in Osteoarthritis Chondrocytes, Exacerbating Cartilage Damage,” The Journal of Gene Medicine 27, no. 1 (2025): e70005.

[213] S. Monteagudo, F. M. F. Cornelis, C. Aznar-Lopez, et al., “DOT1L safeguards Cartilage Homeostasis and Protects Against Osteoarthritis,” Nature Communications 8 (2017): 15889.

[214] R. J. Lories and S. Monteagudo, “Review Article: Is Wnt Signaling an Attractive Target for the Treatment of Osteoarthritis?,” Rheumatology and Therapy 7, no. 2 (2020): 259–270.

[215] J. Wang, X. Wang, X. Ding, T. Huang, D. Song, and H. Tao, “EZH2 is Associated With Cartilage Degeneration in Osteoarthritis by Promoting SDC1 Expression via Histone Methylation of the microRNA-138 Promoter,” Laboratory Investigation 101, no. 5 (2021): 600–611.

[216] C. Yapp, A. J. Carr, A. Price, U. Oppermann, and S. J. Snelling, “H3K27me3 demethylases Regulate in Vitro Chondrogenesis and Chondrocyte Activity in Osteoarthritis,” Arthritis Research & Therapy 18, no. 1 (2016): 158.

[217] H. Zhang, L. Ji, Y. Yang, X. Zhang, Y. Gang, and L. Bai, “The Role of HDACs and HDACi in Cartilage and Osteoarthritis,” Frontiers in Cell and Developmental Biology 8 (2020): 560117.

[218] S. Zhao, J. Zheng, S. Yue, X. Chen, and Y. Dong, “Landscape of Histone Posttranslational Modifications in Osteoarthritis,” Journal of Inflammation Research 18 (2025): 7893–7906.

[219] J. Lu, Y. Sun, Q. Ge, H. Teng, and Q. Jiang, “Histone Deacetylase 4 Alters Cartilage Homeostasis in human Osteoarthritis,” BMC Musculoskeletal Disorders [Electronic Resource] 15 (2014): 438.

[220] K. Cao, L. Wei, Z. Zhang, et al., “Decreased Histone Deacetylase 4 Is Associated With human Osteoarthritis Cartilage Degeneration by Releasing Histone Deacetylase 4 Inhibition of Runt-related Transcription Factor-2 and Increasing Osteoarthritis-related Genes: A Novel Mechanism of human Osteoarthritis Cartilage Degeneration,” Arthritis Research & Therapy 16, no. 6 (2014): 491.

[221] Z. Dong, Z. Ma, M. Yang, et al., “The Level of Histone Deacetylase 4 Is Associated With Aging Cartilage Degeneration and Chondrocyte Hypertrophy,” Journal of Inflammation Research 15 (2022): 3547–3560.

[222] Q. Ning, Y. H. Gan, R. R. Shi, and J. H. Meng, “Effects of HDAC4 on IL-1β-induced Matrix Metalloproteinase Expression Regulated Partially Through the WNT3A/β-catenin Pathway,” Chinese Medical Journal 134, no. 8 (2021): 963–970.

[223] M. J. Barter, A. Butcher, H. Wang, et al., “HDAC6 regulates NF-κB Signalling to Control Chondrocyte IL-1-induced MMP and Inflammatory Gene Expression,” Scientific Reports 12, no. 1 (2022): 6640.

[224] T. Saito, K. Nishida, T. Furumatsu, A. Yoshida, M. Ozawa, and T. Ozaki, “Histone Deacetylase Inhibitors Suppress Mechanical Stress-induced Expression of RUNX-2 and ADAMTS-5 Through the Inhibition of the MAPK Signaling Pathway in Cultured human Chondrocytes,” Osteoarthritis and Cartilage 21, no. 1 (2013): 165–174.

[225] Y. Gao, K. Wang, C. Shi, Y. Gao, and D. Q. Kong, “Obacunone Acts as a Histone Deacetylase 1 Inhibitor to Limit p38MAPK Signaling and Alleviate Osteoarthritis Progression,” Journal of Orthopaedic Surgery and Research 20, no. 1 (2025): 441.

[226] P. K. Sacitharan, G. Bou-Gharios, and J. R. Edwards, “SIRT1 directly Activates Autophagy in human Chondrocytes,” Cell Death Discovery 6 (2020): 41.

[227] Q. Lu, P. Liu, Z. Miao, D. Luo, S. Li, and M. Lu, “SIRT1 restoration Enhances Chondrocyte Autophagy in Osteoarthritis Through PTEN-mediated EGFR Ubiquitination,” Cell Death Discovery 8, no. 1 (2022): 203.

[228] A. A. Papageorgiou, A. Goutas, V. Trachana, and A. Tsezou, “Dual Role of SIRT1 in Autophagy and Lipid Metabolism Regulation in Osteoarthritic Chondrocytes,” Medicina (Kaunas, Lithuania) 57, no. 11 (2021): 1203.

[229] C. Liang, H. Xing, C. Wang, X. Xu, Y. Hao, and B. Qiu, “Resveratrol Protection Against IL-1β-induced Chondrocyte Damage via the SIRT1/FOXO1 Signaling Pathway,” Journal of Orthopaedic Surgery and Research 17, no. 1 (2022): 406.

[230] M. L. Ji, H. Jiang, Z. Li, et al., “Sirt6 attenuates Chondrocyte Senescence and Osteoarthritis Progression,” Nature Communications 13, no. 1 (2022): 7658.

[231] J. A. Collins, C. J. Kim, A. Coleman, et al., “Cartilage-specific Sirt6 Deficiency Represses IGF-1 and Enhances Osteoarthritis Severity in Mice,” Annals of the Rheumatic Diseases 82, no. 11 (2023): 1464–1473.

[232] L. W. Mao, Q. Y. Jiang, N. Meng, et al., “Sirt6 promotes DNA Damage Repair in Osteoarthritis Chondrocytes by Activating the Keap1/Nrf2/HO-1 Signaling Pathway,” Cell Cycle 23, no. 2 (2024): 205–217.

[233] H. Y. Joo, A. Jones, C. Yang, et al., “Regulation of Histone H2A and H2B Deubiquitination and Xenopus Development by USP12 and USP46,” Journal of Biological Chemistry 286, no. 9 (2011): 7190–7201.

[234] J. Cao and Q. Yan, “Histone Ubiquitination and Deubiquitination in Transcription, DNA Damage Response, and Cancer,” Frontiers in Oncology 2 (2012): 26.

[235] C. H. Loh and G. J. C. Veenstra, “The Role of Polycomb Proteins in Cell Lineage Commitment and Embryonic Development,” Epigenomes 6, no. 3 (2022): 23.

[236] Y. Zhang, J. Wang, D. Hua, et al., “Histone Modifications: Unveiling the Epigenetic Enigma of Degenerative Skeletal Diseases,” Journal of Orthopaedic Translation 55 (2025): 245–266.

[237] P. Xu, G. Ye, X. Xu, et al., “Inhibition of WAC Alleviates the Chondrocyte Proinflammatory Secretory Phenotype and Cartilage Degradation via H2BK120ub1 and H3K27me3 Coregulation,” Acta Pharmaceutica Sinica B 15, no. 8 (Aug 2025): 4064–4077.

[238] K. Wei, C. Zhou, Z. Shu, et al., “MYSM1 attenuates Osteoarthritis by Recruiting PP2A to Deubiquitinate and Dephosphorylate RIPK2,” Bone Research 13, no. 1 (2025): 3.

[239] Q. Zhou, Z. Xiao, R. Zhou, et al., “Ubiquitin-specific Protease 3 Targets TRAF6 for Deubiquitination and Suppresses IL-1β Induced Chondrocyte Apoptosis,” Biochemical and Biophysical Research Communications 514, no. 2 (2019): 482–489.

[240] L. Yang, Z. Wang, C. Zou, Y. Mi, H. Tang, and X. Wu, “Ubiquitin-specific Protease 49 Attenuates IL-1β-induced Rat Primary Chondrocyte Apoptosis by Facilitating Axin Deubiquitination and Subsequent Wnt/β-catenin Signaling Cascade Inhibition,” Molecular and Cellular Biochemistry 474, no. 1-2 (2020): 263–275.

[241] X. Chen, T. Ma, Y. Chen, Q. Sun, H. Wang, and Y. Wang, “USP14 promotes Osteoarthritis Progression by Deubiquitinating FZD8 to Activate the Wnt/β-catenin Signaling Pathway,” Immunobiology 230, no. 3 (2025): 152905.

[242] J. Sui, F. Dai, J. Shi, and C. Zhou, “Ubiquitin-specific Peptidase 25 Exacerbated Osteoarthritis Progression Through Facilitating TXNIP Ubiquitination and NLRP3 Inflammasome Activation,” Journal of Orthopaedic Surgery and Research 18, no. 1 (2023): 762.

[243] Z. Yuan, G. Chen, Y. Li, Z. Zhao, and H. Zhang, “Deubiquitinating Enzymes in Osteoarthritis: From Mechanisms to Therapeutic,” Orthopedic Reviews (Pavia) 17 (2025): 144733.

[244] H. M. Li, H. L. Guo, C. Xu, et al., “Inhibition of Glycolysis by Targeting Lactate Dehydrogenase A Facilitates Hyaluronan Synthase 2 Synthesis in Synovial Fibroblasts of Temporomandibular Joint Osteoarthritis,” Bone 141 (2020): 115584.

[245] Y. Hu, Z. He, Z. Li, et al., “Lactylation: The Novel Histone Modification Influence on Gene Expression, Protein Function, and Disease,” Clinical Epigenetics 16, no. 1 (2024): 72.

[246] F. Lu, Y. Yu, G. Yin, et al., “FSTL1 Orchestrates Metabolic-Epigenetic Crosstalk: Glycolysis-Dependent H3K18 Lactylation Drives Cartilage Fibrosis in Osteoarthritis,” Advanced Science (Weinheim) 13, no. 8 (2026): e12002.

[247] J. Xia, Z. Qiao, X. Hao, and Y. Zhang, “LDHA-induced Histone Lactylation Mediates the Development of Osteoarthritis Through Regulating the Transcription Activity of TPI1 Gene,” Autoimmunity 57, no. 1 (2024): 2384889.

[248] Y. Zhang, C. Y. Zhao, Z. Zhou, C. C. Li, and Q. Wang, “The Effect of Lactate Dehydrogenase B and Its Mediated Histone Lactylation on Chondrocyte Ferroptosis During Osteoarthritis,” Journal of Orthopaedic Surgery and Research 20, no. 1 (2025): 493.

[249] W. Lan, X. Chen, H. Yu, et al., “UGDH Lactylation Aggravates Osteoarthritis by Suppressing Glycosaminoglycan Synthesis and Orchestrating Nucleocytoplasmic Transport to Activate MAPK Signaling,” Advanced Science (Weinheim) 12, no. 20 (2025): e2413709.

[250] Y. Qian, S. Wang, Y. Sha, et al., “Hydrogel-guided p-LOX Nanodrug Delivery Modulates Metabolic Microenvironment for Cartilage Repair in Osteoarthritis,” Biomaterials 328 (2025): 123806.

[251] B. J. Lukasak, M. M. Mitchener, L. Kong, et al., “TGM2-mediated Histone Transglutamination Is Dictated by Steric Accessibility,” Proceedings of the National Academy of Sciences of the United States of America 119, no. 43 (2022): e2208672119.

[252] L. A. Farrelly, R. E. Thompson, S. Zhao, et al., “Histone Serotonylation Is a Permissive Modification That Enhances TFIID Binding to H3K4me3,” Nature 567, no. 7749 (2019): 535–539.

[253] Q. Zheng, B. H. Weekley, D. A. Vinson, et al., “Bidirectional Histone Monoaminylation Dynamics Regulate Neural Rhythmicity,” Nature 637, no. 8047 (2025): 974–982.

[254] F. Rossin, F. Ciccosanti, M. D'Eletto, L. Occhigrossi, G. M. Fimia, and M. Piacentini, “Type 2 Transglutaminase in the Nucleus: The New Epigenetic Face of a Cytoplasmic Enzyme,” Cellular and Molecular Life Sciences 80, no. 2 (2023): 52.

[255] Y. Li, H. Sun, X. Liu, et al., “Transglutaminase 2 Inhibitors Attenuate Osteoarthritic Degeneration of TMJ-osteoarthritis by Suppressing NF-κB Activation,” International Immunopharmacology 114 (2023): 109486.

[256] Q. Yao, T. He, J. Y. Liao, et al., “Noncoding RNAs in Skeletal Development and Disorders,” Biological Research 57, no. 1 (2024): 16.

[257] S. Radbakhsh, M. Najar, M. Merimi, et al., “RNA Modifications in Osteoarthritis: Epitranscriptomic Insights Into Pathogenesis and Therapeutic Targets,” International Journal of Molecular Sciences 26, no. 10 (2025): 4955.

[258] Y. Zhao, Q. Xiang, S. Tian, et al., “Noncoding RNA as a Crucial Epigenetic Modulator in the Degeneration of the Ligamentum Flavum,” Experimental & Molecular Medicine 56, no. 12 (2024): 2551–2558.

[259] X. Zhu, T. Chen, J. Dong, et al., “Targeting Epigenetic Modifiers in Osteoarthritis: From Biological Insights to Pre-clinical Practice,” Epigenetics Insights 18, no. 1 (2025): e012.

[260] Y. Chen, H. Huang, W. Zhong, L. Li, Y. Lu, and H. B. Si, “miR-140-5p Protects Cartilage Progenitor/Stem Cells From Fate Changes in Knee Osteoarthritis,” International Immunopharmacology 114 (2023): 109576.

[261] Y. Liu, Y. Zeng, H. B. Si, L. Tang, H. Q. Xie, and B. Shen, “Exosomes Derived from Human Urine-Derived Stem Cells Overexpressing miR-140-5p Alleviate Knee Osteoarthritis through Downregulation of VEGFA in a Rat Model,” American Journal of Sports Medicine 50, no. 4 (2022): 1088–1105.

[262] H. Endisha, P. Datta, A. Sharma, et al., “MicroRNA-34a-5p Promotes Joint Destruction during Osteoarthritis,” Arthritis Rheumatology 73, no. 3 (2021): 426–439.

[263] Y. Ji, L. Xiong, G. Zhang, et al., “Synovial Fluid Exosome-derived miR-182-5p Alleviates Osteoarthritis by Downregulating TNFAIP8 and Promoting Autophagy Through LC3 Signaling,” International Immunopharmacology 125, no. Pt A (2023): 111177.

[264] X. Zhang, C. R. Huang, S. Pan, et al., “Long Non-coding RNA SNHG15 Is a Competing Endogenous RNA of miR-141-3p That Prevents Osteoarthritis Progression by Upregulating BCL2L13 Expression,” International Immunopharmacology 83 (2020): 106425.

[265] Z. Zhao, Z. Wang, L. Pei, X. Zhou, and Y. Liu, “Long Non-coding Ribonucleic Acid AFAP1-AS1 Promotes Chondrocyte Proliferation via the miR-512-3p/Matrix Metallopeptidase 13 (MMP-13) Axis,” Bioengineered 13, no. 3 (2022): 5386–5395.

[266] J. He, L. Wang, Y. Ding, H. Liu, and G. Zou, “lncRNA FER1L4 Is Dysregulated in Osteoarthritis and Regulates IL-6 Expression in human Chondrocyte Cells,” Scientific Reports 11, no. 1 (2021): 13032.

[267] C. Chen, P. Yin, S. Hu, X. Sun, and B. Li, “Circular RNA-9119 Protects IL-1β-treated Chondrocytes From Apoptosis in an Osteoarthritis Cell Model by Intercepting the microRNA-26a/PTEN Axis,” Life Sciences 256 (2020): 117924.

[268] P. Wahafu, A. Xu, B. Zhao, Y. Tuo, and J. Yang, “Circ_0005526 contributes to Interleukin-1β-induced Chondrocyte Injury in Osteoarthritis via Upregulating Transcription Factor 4 by Interacting With miR-142-5p,” Bioengineered 13, no. 4 (2022): 8407–8418.

[269] L. Shen, C. Ji, J. Lin, and H. Yang, “Regulation of circADAMTS6-miR-324-5p-PIK3R3 ceRNA Pathway May be a Novel Mechanism of IL-1β-induced Osteoarthritic Chondrocytes,” Journal of Bone and Mineral Metabolism 40, no. 3 (2022): 389–401.

[270] S. Miyaki, T. Sato, A. Inoue, et al., “MicroRNA-140 Plays Dual Roles in both Cartilage Development and Homeostasis,” Genes & Development 24, no. 11 (2010): 1173–1185.

[271] T. A. Karlsen, G. A. de Souza, B. Ødegaard, L. Engebretsen, and J. E. Brinchmann, “microRNA-140 Inhibits Inflammation and Stimulates Chondrogenesis in a Model of Interleukin 1β-induced Osteoarthritis,” Molecular Therapy Nucleic Acids 5, no. 10 (2016): e373.

[272] K. Yamasaki, T. Nakasa, S. Miyaki, et al., “Expression of MicroRNA-146a in Osteoarthritis Cartilage,” Arthritis and Rheumatism 60, no. 4 (2009): 1035–1041.

[273] X. Zhang, C. Wang, J. Zhao, et al., “miR-146a Facilitates Osteoarthritis by Regulating Cartilage Homeostasis via Targeting Camk2d and Ppp3r2,” Cell Death & Disease 8, no. 4 (2017): e2734.

[274] T. Yang, C. Li, Y. Li, et al., “MicroRNA-146a-5p Alleviates the Pathogenesis of Osteoarthritis by Inhibiting SDF-1/CXCR4-induced Chondrocyte Autophagy,” International Immunopharmacology 117 (2023): 109938.

[275] S. Yan, M. Wang, J. Zhao, et al., “MicroRNA-34a Affects Chondrocyte Apoptosis and Proliferation by Targeting the SIRT1/p53 Signaling Pathway During the Pathogenesis of Osteoarthritis,” International Journal of Molecular Medicine 38, no. 1 (2016): 201–209.

[276] M. M. Abouheif, T. Nakasa, H. Shibuya, T. Niimoto, W. Kongcharoensombat, and M. Ochi, “Silencing microRNA-34a Inhibits Chondrocyte Apoptosis in a Rat Osteoarthritis Model in Vitro,” Rheumatology 49, no. 11 (2010): 2054–2060.

[277] Y. Ito, T. Matsuzaki, F. Ayabe, et al., “Both microRNA-455-5p and -3p Repress Hypoxia-inducible Factor-2α Expression and Coordinately Regulate Cartilage Homeostasis,” Nature Communications 12, no. 1 (2021): 4148.

[278] Y. Zhang, S. Li, P. Jin, et al., “Dual Functions of microRNA-17 in Maintaining Cartilage Homeostasis and Protection Against Osteoarthritis,” Nature Communications 13, no. 1 (2022): 2447.

[279] D. Kang, J. Shin, Y. Cho, et al., “Stress-activated miR-204 Governs Senescent Phenotypes of Chondrocytes to Promote Osteoarthritis Development,” Science Translational Medicine 11, no. 486 (2019): eaar6659.

[280] Y. Tao, J. Zhou, Z. Wang, et al., “Human Bone Mesenchymal Stem Cells-derived Exosomal miRNA-361-5p Alleviates Osteoarthritis by Downregulating DDX20 and Inactivating the NF-κB Signaling Pathway,” Bioorganic Chemistry 113 (2021): 104978.

[281] C. Cheng, Y. Tian, R. Yang, et al., “miR-5581 Contributes to Osteoarthritis by Targeting NRF1 to Disturb the Proliferation and Functions of Chondrocytes,” American Journal of Pathology 193, no. 9 (2023): 1234–1247.

[282] Q. Liu, X. Zhang, L. Dai, et al., “Long Noncoding RNA Related to Cartilage Injury Promotes Chondrocyte Extracellular Matrix Degradation in Osteoarthritis,” Arthritis Rheumatology 66, no. 4 (2014): 969–978.

[283] Y. F. Li, S. H. Li, Y. Liu, and Y. T. Luo, “Long Noncoding RNA CIR Promotes Chondrocyte Extracellular Matrix Degradation in Osteoarthritis by Acting as a Sponge for Mir-27b,” Cellular Physiology and Biochemistry 43, no. 2 (2017): 602–610.

[284] P. Dou, R. Hu, W. Zhu, et al., “Long Non-coding RNA HOTAIR Promotes Expression of ADAMTS-5 in human Osteoarthritic Articular Chondrocytes,” Die Pharmazie 72, no. 2 (2017): 113–117.

[285] J. Hu, Z. Wang, Y. Shan, Y. Pan, J. Ma, and L. Jia, “Long Non-coding RNA HOTAIR Promotes Osteoarthritis Progression via miR-17-5p/FUT2/β-catenin Axis,” Cell Death & Disease 9, no. 7 (2018): 711.

[286] Y. Yang, D. Xing, Y. Wang, H. Jia, B. Li, and J. J. Li, “A Long Non-coding RNA, HOTAIR, Promotes Cartilage Degradation in Osteoarthritis by Inhibiting WIF-1 Expression and Activating Wnt Pathway,” BMC Molecular and Cell Biology 21, no. 1 (2020): 53.

[287] J. Lu, Z. Wu, and Y. Xiong, “Knockdown of Long Noncoding RNA HOTAIR Inhibits Osteoarthritis Chondrocyte Injury by miR-107/CXCL12 Axis,” Journal of Orthopaedic Surgery and Research 16, no. 1 (2021): 410.

[288] W. Su, W. Xie, Q. Shang, and B. Su, “The Long Noncoding RNA MEG3 Is Downregulated and Inversely Associated With VEGF Levels in Osteoarthritis,” BioMed Research International 2015 (2015): 356893.

[289] K. Chen, H. Zhu, M. Q. Zheng, and Q. R. Dong, “LncRNA MEG3 Inhibits the Degradation of the Extracellular Matrix of Chondrocytes in Osteoarthritis via Targeting miR-93/TGFBR2 Axis,” Cartilage 13, no. 2_suppl (2021): 1274S–1284S.

[290] D. Li, Y. Sun, Y. Wan, X. Wu, and W. Yang, “LncRNA NEAT1 Promotes Proliferation of Chondrocytes via Down-regulation of miR-16-5p in Osteoarthritis,” The Journal of Gene Medicine 22, no. 9 (2020): e3203.

[291] G. Zhang, Y. Wu, D. Xu, and X. Yan, “Long Noncoding RNA UFC1 Promotes Proliferation of Chondrocyte in Osteoarthritis by Acting as a Sponge for miR-34a,” Dna and Cell Biology 35, no. 11 (2016): 691–695.

[292] M. Jiang, J. Liu, T. Luo, Q. Chen, M. Lu, and D. Meng, “LncRNA PACER Is Down-regulated in Osteoarthritis and Regulates Chondrocyte Apoptosis and lncRNA HOTAIR Expression,” Bioscience Reports 39, no. 6 (2019): BSR20190404.

[293] S. Shen, Y. Wu, J. Chen, et al., “CircSERPINE2 protects Against Osteoarthritis by Targeting miR-1271 and ETS-related Gene,” Annals of the Rheumatic Diseases 78, no. 6 (2019): 826–836.

[294] Q. Zhang, X. Qiao, and W. Xia, “CircSERPINE2 weakens IL-1β-caused Apoptosis and Extracellular Matrix Degradation of Chondrocytes by Regulating miR-495/TGFBR2 Axis,” Bioscience Reports 40, no. 11 (2020): BSR20201601.

[295] W. Ni, C. Jiang, Y. Wu, et al., “CircSLC7A2 protects Against Osteoarthritis Through Inhibition of the miR-4498/TIMP3 Axis,” Cell Proliferation 54, no. 6 (2021): e13047.

[296] P. Shen, Y. Yang, G. Liu, et al., “CircCDK14 protects Against Osteoarthritis by Sponging miR-125a-5p and Promoting the Expression of Smad2,” Theranostics 10, no. 20 (2020): 9113–9131.

[297] C. Zhao, X. Li, G. Sun, et al., “CircFOXO3 protects Against Osteoarthritis by Targeting Its Parental Gene FOXO3 and Activating PI3K/AKT-mediated Autophagy,” Cell Death & Disease 13, no. 11 (2022): 932.

[298] H. Zhu, Y. Hu, C. Wang, X. Zhang, and D. He, “CircGCN1L1 promotes Synoviocyte Proliferation and Chondrocyte Apoptosis by Targeting miR-330-3p and TNF-α in TMJ Osteoarthritis,” Cell Death & Disease 11, no. 4 (2020): 284.

[299] A. J. Gibbs, B. Gray, J. A. Wallis, et al., “Recommendations for the Management of Hip and Knee Osteoarthritis: A Systematic Review of Clinical Practice Guidelines,” Osteoarthritis and Cartilage 31, no. 10 (2023): 1280–1292.

[300] S. L. Kolasinski, T. Neogi, M. C. Hochberg, et al., “2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee,” Arthritis Rheumatology 72, no. 2 (2020): 220–233.

[301] T. Moseng, T. P. M. Vliet Vlieland, S. Battista, et al., “EULAR Recommendations for the Non-pharmacological Core Management of Hip and Knee Osteoarthritis: 2023 Update,” Annals of the Rheumatic Diseases 83, no. 6 (2024): 730–740.

[302] L. Mo, B. Jiang, T. Mei, and D. Zhou, “Exercise Therapy for Knee Osteoarthritis: A Systematic Review and Network Meta-analysis,” Orthopaedic Journal of Sports Medicine 11, no. 5 (2023): 23259671231172773.

[303] R. M. Ferreira, P. N. Martins, and R. S. Gonçalves, “Non-pharmacological and Non-surgical Interventions to Manage Patients With Knee Osteoarthritis: An Umbrella Review 5-year Update,” Osteoarthritis and Cartilage Open 6, no. 3 (2024): 100497.

[304] T. Haber, B. J. Lawford, K. Bennell, M. Holden, D. K. White, and R. S. Hinman, “Recent Highlights and Uncertainties in Exercise Management of Knee Osteoarthritis,” Journal of Physiotherapy 71, no. 3 (Jul 2025): 158–166.

[305] M. Sabha and M. C. Hochberg, “Non-surgical Management of Hip and Knee Osteoarthritis; Comparison of ACR/AF and OARSI 2019 and VA/DoD 2020 Guidelines,” Osteoarthritis and Cartilage Open 4, no. 1 (2022): 100232.

[306] E. K. Robson, R. K. Hodder, S. J. Kamper, et al., “Effectiveness of Weight-Loss Interventions for Reducing Pain and Disability in People With Common Musculoskeletal Disorders: A Systematic Review With Meta-Analysis,” Journal of Orthopaedic and Sports Physical Therapy 50, no. 6 (2020): 319–333.

[307] I. J. H. Chu, A. Y. T. Lim, and C. L. W. Ng, “Effects of Meaningful Weight Loss Beyond Symptomatic Relief in Adults With Knee Osteoarthritis and Obesity: A Systematic Review and Meta-analysis,” Obesity Reviews 19, no. 11 (2018): 1597–1607.

[308] S. P. Messier, A. E. Resnik, D. P. Beavers, et al., “Intentional Weight Loss in Overweight and Obese Patients With Knee Osteoarthritis: Is More Better?,” Arthritis Care Research (Hoboken) 70, no. 11 (2018): 1569–1575.

[309] R. D. Gaasbeek, B. E. Groen, B. Hampsink, R. J. van Heerwaarden, and J. Duysens, “Valgus Bracing in Patients With Medial Compartment Osteoarthritis of the Knee. A Gait Analysis Study of a New Brace,” Gait & Posture 26, no. 1 (2007): 3–10.

[310] X. Robert-Lachaine, Y. Dessery, É. L. Belzile, and P. Corbeil, “Knee Braces and Foot Orthoses Multimodal Treatment of Medial Knee Osteoarthritis,” Gait & Posture 96 (2022): 251–256.

[311] B. Joo, J. L. Marquez, and P. G. Osmotherly, “An Observational Study of the Impact of Professional Walking Aid Prescription on Gait Parameters for Individuals With Suspected Balance Impairments,” Heliyon 10, no. 18 (2024): e37649.

[312] T. M. van Raaij, M. Reijman, R. W. Brouwer, S. M. Bierma-Zeinstra, and J. A. Verhaar, “Medial Knee Osteoarthritis Treated by Insoles or Braces: A Randomized Trial,” Clinical Orthopaedics and Related Research 468, no. 7 (2010): 1926–1932.

[313] W. C. Hsu, L. W. Chou, H. Y. Chiu, C. W. Hsieh, and W. P. Hu, “A Study on the Effects of Lateral-Wedge Insoles on Plantar-Pressure Pattern for Medial Knee Osteoarthritis Using the Wearable Sensing Insole,” Sensors (Basel) 23, no. 1 (2022): 84.

[314] S. Reichenbach, P. Jüni, C. A. Hincapié, et al., “Effect of Transcutaneous Electrical Nerve Stimulation (TENS) on Knee Pain and Physical Function in Patients With Symptomatic Knee Osteoarthritis: The ETRELKA Randomized Clinical Trial,” Osteoarthritis and Cartilage 30, no. 3 (2022): 426–435.

[315] N. Katagiri, K. Kawashima, M. Hamasuna, M. Motoyama, and T. Yamaguchi, “Effects of TENS With Home Exercise Improve Pain and Muscle Strength in Older Adults With Pre-radiographic to Mild Knee Osteoarthritis,” Scientific Reports 15, no. 1 (2025): 39992.

[316] P. Tang, T. Wen, W. Lu, et al., “The Efficacy of Extracorporeal Shock Wave Therapy for Knee Osteoarthritis: An Umbrella Review,” International Journal of Surgery 110, no. 4 (2024): 2389–2395.

[317] R. K. Nelligan, R. S. Hinman, J. Kasza, S. J. C. Crofts, and K. L. Bennell, “Effects of a Self-directed Web-Based Strengthening Exercise and Physical Activity Program Supported by Automated Text Messages for People With Knee Osteoarthritis: A Randomized Clinical Trial,” JAMA Internal Medicine 181, no. 6 (2021): 776–785.

[318] S. A. Gohir, F. Eek, A. Kelly, A. Abhishek, and A. M. Valdes, “Effectiveness of Internet-Based Exercises Aimed at Treating Knee Osteoarthritis: The iBEAT-OA Randomized Clinical Trial,” JAMA Network Open 4, no. 2 (2021): e210012.

[319] K. L. Bennell, B. J. Lawford, C. Keating, et al., “Comparing Video-Based, Telehealth-Delivered Exercise and Weight Loss Programs With Online Education on Outcomes of Knee Osteoarthritis: A Randomized Trial,” Annals of Internal Medicine 175, no. 2 (2022): 198–209.

[320] S. J. Zhu, R. S. Hinman, R. K. Nelligan, et al., “Online Unsupervised Tai Chi Intervention for Knee Pain and Function in People With Knee Osteoarthritis: The RETREAT Randomized Clinical Trial,” JAMA Internal Medicine 186, no. 1 (2026): 15–25.

[321] B. J. Abafita, A. Singh, D. Aitken, et al., “Yoga or Strengthening Exercise for Knee Osteoarthritis: A Randomized Clinical Trial,” JAMA Network Open 8, no. 4 (2025): e253698.

[322] V. Dieter, P. Janssen, and I. Krauss, “Efficacy of the mHealth-Based Exercise Intervention re.flex for Patients With Knee Osteoarthritis: Pilot Randomized Controlled Trial,” JMIR Mhealth Uhealth 12 (2024): e54356.

[323] M. Gueugnon, I. Fournel, A. L. Soilly, et al., “Effectiveness, Safety, and Cost-utility of a Knee Brace in Medial Knee Osteoarthritis: The ERGONOMIE Randomized Controlled Trial,” Osteoarthritis and Cartilage 29, no. 4 (2021): 491–501.

[324] N. K. Arden, T. A. Perry, R. R. Bannuru, et al., “Non-surgical Management of Knee Osteoarthritis: Comparison of ESCEO and OARSI 2019 Guidelines,” Nature Reviews Rheumatology 17, no. 1 (2021): 59–66.

[325] B. R. da Costa, T. V. Pereira, P. Saadat, et al., “Effectiveness and Safety of Non-steroidal Anti-inflammatory Drugs and Opioid Treatment for Knee and Hip Osteoarthritis: Network Meta-analysis,” Bmj 375 (2021): n2321.

[326] T. Ling, J. J. Li, R. J. Xu, B. Wang, and W. H. Ge, “Topical Diclofenac Solution for Osteoarthritis of the Knee: An Updated Meta-Analysis of Randomized Controlled Trials,” BioMed Research International 2020 (2020): 1758071.

[327] Y. Uchio, H. Enomoto, L. Alev, et al., “A Randomized, Double-blind, Placebo-controlled Phase III Trial of Duloxetine in Japanese Patients With Knee Pain due to Osteoarthritis,” Journal of Pain Research 11 (2018): 809–821.

[328] G. Wang, L. Bi, X. Li, et al., “Efficacy and Safety of Duloxetine in Chinese Patients With Chronic Pain due to Osteoarthritis: A Randomized, Double-blind, Placebo-controlled Study,” Osteoarthritis and Cartilage 25, no. 6 (2017): 832–838.

[329] J. Y. Reginster, J. Dudler, T. Blicharski, and K. Pavelka, “Pharmaceutical-grade Chondroitin Sulfate Is as Effective as celecoxib and Superior to Placebo in Symptomatic Knee Osteoarthritis: The ChONdroitin versus CElecoxib versus Placebo Trial (CONCEPT),” Annals of the Rheumatic Diseases 76, no. 9 (2017): 1537–1543.

[330] Y. B. Park and J. H. Kim, “Effectiveness and Safety of SYSADOAs Used in Eastern and Western Regions for the Treatment of Knee Osteoarthritis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials-SYSADOAs Are Effective and Safe for Knee OA,” Medicina (Kaunas, Lithuania) 61, no. 2 (2025): 331.

[331] J. P. Pelletier, J. P. Raynauld, M. Dorais, et al., “An International, Multicentre, Double-blind, Randomized Study (DISSCO): Effect of diacerein vs celecoxib on Symptoms in Knee Osteoarthritis,” Rheumatology 59, no. 12 (2020): 3858–3868.

[332] T. E. McAlindon, M. P. LaValley, W. F. Harvey, et al., “Effect of Intra-articular Triamcinolone vs Saline on Knee Cartilage Volume and Pain in Patients With Knee Osteoarthritis: A Randomized Clinical Trial,” Jama 317, no. 19 (2017): 1967–1975.

[333] T. V. Pereira, P. Jüni, P. Saadat, et al., “Viscosupplementation for Knee Osteoarthritis: Systematic Review and Meta-analysis,” Bmj 378 (2022): e069722.

[334] K. L. Bennell, K. L. Paterson, B. R. Metcalf, et al., “Effect of Intra-articular Platelet-Rich Plasma vs Placebo Injection on Pain and Medial Tibial Cartilage Volume in Patients With Knee Osteoarthritis: The RESTORE Randomized Clinical Trial,” Jama 326, no. 20 (2021): 2021–2030.

[335] V. B. Kraus, B. Burnett, J. Coindreau, et al., “Application of Biomarkers in the Development of Drugs Intended for the Treatment of Osteoarthritis,” Osteoarthritis and Cartilage 19, no. 5 (2011): 515–542.

[336] P. Jiang, K. Hu, L. Jin, and Z. Luo, “A Brief Review of Current Treatment Options for Osteoarthritis Including Disease-modifying Osteoarthritis Drugs (DMOADs) and Novel Therapeutics,” Annals of Medicine and Surgery (London) 86, no. 7 (2024): 4042–4048.

[337] F. Eckstein, M. C. Hochberg, H. Guehring, et al., “Long-term Structural and Symptomatic Effects of Intra-articular Sprifermin in Patients With Knee Osteoarthritis: 5-year Results From the FORWARD Study,” Annals of the Rheumatic Diseases 80, no. 8 (2021): 1062–1069.

[338] H. Guehring, F. Moreau, B. Daelken, et al., “The Effects of sprifermin on Symptoms and Structure in a Subgroup at Risk of Progression in the FORWARD Knee Osteoarthritis Trial,” Seminars in Arthritis and Rheumatism 51, no. 2 (2021): 450–456.

[339] M. C. Hochberg, J. A. Carrino, T. J. Schnitzer, et al., “Long-Term Safety and Efficacy of Subcutaneous Tanezumab versus Nonsteroidal Antiinflammatory Drugs for Hip or Knee Osteoarthritis: A Randomized Trial,” Arthritis Rheumatology 73, no. 7 (2021): 1167–1177.

[340] T. Neogi, D. J. Hunter, M. Churchill, et al., “Observed Efficacy and Clinically Important Improvements in Participants With Osteoarthritis Treated With Subcutaneous Tanezumab: Results From a 56-week Randomized NSAID-controlled Study,” Arthritis Research & Therapy 24, no. 1 (2022): 78.

[341] Y. Yazici, T. E. McAlindon, A. Gibofsky, et al., “A Phase 2b Randomized Trial of lorecivivint, a Novel Intra-articular CLK2/DYRK1A Inhibitor and Wnt Pathway Modulator for Knee Osteoarthritis,” Osteoarthritis and Cartilage 29, no. 5 (2021): 654–666.

[342] C. R. Harrell, B. S. Markovic, C. Fellabaum, A. Arsenijevic, and V. Volarevic, “Mesenchymal Stem Cell-based Therapy of Osteoarthritis: Current Knowledge and Future Perspectives,” Biomedicine & Pharmacotherapy 109 (2019): 2318–2326.

[343] X. Zhang, T. Liu, C. Ran, et al., “Immunoregulatory Paracrine Effect of Mesenchymal Stem Cells and Mechanism in the Treatment of Osteoarthritis,” Frontiers in Cell and Developmental Biology 12 (2024): 1411507.

[344] K. I. Kim, M. C. Lee, J. H. Lee, et al., “Clinical Efficacy and Safety of the Intra-articular Injection of Autologous Adipose-Derived Mesenchymal Stem Cells for Knee Osteoarthritis: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial,” American Journal of Sports Medicine 51, no. 9 (2023): 2243–2253.

[345] Y. M. Pers, H. Schrezenmeier, S. Fleury-Cappellesso, et al., “Effect of Intra-articular Adipose-derived Mesenchymal Stromal Cell versus Placebo Injection on Pain and Function in Patients With Knee Osteoarthritis: The ADIPOA2 Phase 2b Randomised Clinical Trial,” Annals of the Rheumatic Diseases 84, no. 12 (2025): 2103–2114.

[346] K. W. Barfod, L. Blønd, R. K. Mikkelsen, et al., “Treatment of Knee Osteoarthritis With a Single Injection of Autologous Micro-fragmented Adipose Tissue Is Not Superior to a Placebo Saline Injection: A Blinded Randomised Controlled Trial With 2-year Follow-up,” British Journal of Sports Medicine 59, no. 17 (2025): 1219–1227.

[347] K. Mautner, M. Gottschalk, S. D. Boden, et al., “Cell-based versus Corticosteroid Injections for Knee Pain in Osteoarthritis: A Randomized Phase 3 Trial,” Nature Medicine 29, no. 12 (2023): 3120–3126.

[348] C. F. Chen, C. C. Hu, C. T. Wu, et al., “Treatment of Knee Osteoarthritis With Intra-articular Injection of Allogeneic Adipose-derived Stem Cells (ADSCs) ELIXCYTE®: A Phase I/II, Randomized, Active-control, Single-blind, Multiple-center Clinical Trial,” Stem Cell Research & Therapy 12, no. 1 (2021): 562.

[349] C. Wu, Y. He, Y. Yao, H. Yang, and F. Lu, “Exosomes Treating Osteoarthritis: Hope With Challenge,” Heliyon 9, no. 1 (2023): e13152.

[350] Y. Wang, Y. Kong, J. Du, et al., “Injection of human Umbilical Cord Mesenchymal Stem Cells Exosomes for the Treatment of Knee Osteoarthritis: From Preclinical to Clinical Research,” Journal of Translational Medicine 23, no. 1 (2025): 641.

[351] W. Liu, A. Liu, X. Li, et al., “Dual-engineered Cartilage-targeting Extracellular Vesicles Derived From Mesenchymal Stem Cells Enhance Osteoarthritis Treatment via miR-223/NLRP3/Pyroptosis Axis: Toward a Precision Therapy,” Bioactive Materials 30 (2023): 169–183.

[352] B. Li, E. Shen, Z. Wu, et al., “BMSC-Derived Exosomes Attenuate Rat Osteoarthritis by Regulating Macrophage Polarization Through PINK1/Parkin Signaling Pathway,” Cartilage (2024): 19476035241245805, https://doi.org/10.1177/19476035241245805.

[353] W. Sun, S. Qu, M. Ji, Y. Sun, and B. Hu, “BMP-7 Modified Exosomes Derived From Synovial Mesenchymal Stem Cells Attenuate Osteoarthritis by M2 Polarization of Macrophages,” Heliyon 9, no. 9 (2023): e19934.

[354] B. Yin, J. Xu, J. Lu, et al., “Responsive Hydrogel-Based Drug Delivery Platform for Osteoarthritis Treatment,” Gels 10, no. 11 (2024): 696.

[355] Y. Zhang, X. Wang, J. Chen, et al., “Exosomes Derived From Platelet-rich Plasma Administration in Site Mediate Cartilage Protection in Subtalar Osteoarthritis,” Journal of Nanobiotechnology 20, no. 1 (2022): 56.

[356] L. Yang, L. Shao, P. Hao, et al., “Self-Assembling Hydrogels of Naproxen-Conjugated Peptides for Osteoarthritis Treatment,” Theranostics 15, no. 17 (2025): 8779–8794.

[357] W. Li, Z. Shi, H. Jing, et al., “Streamlined Metal-based Hydrogel Facilitates Stem Cell Differentiation, Extracellular Matrix Homeostasis and Cartilage Repair in Male Rats,” Nature Communications 16, no. 1 (2025): 4344.

[358] J. Zhu, S. Yang, Y. Qi, et al., “Stem Cell-homing Hydrogel-based miR-29b-5p Delivery Promotes Cartilage Regeneration by Suppressing Senescence in an Osteoarthritis Rat Model,” Science Advances 8, no. 13 (2022): eabk0011.

[359] W. Qin, Z. Ma, G. Bai, et al., “Neurovascularization Inhibiting Dual Responsive Hydrogel for Alleviating the Progression of Osteoarthritis,” Nature Communications 16, no. 1 (2025): 1390.

[360] Y. Yang, X. Zhao, S. Wang, et al., “Ultra-durable Cell-free Bioactive Hydrogel With Fast Shape Memory and on-demand Drug Release for Cartilage Regeneration,” Nature Communications 14, no. 1 (2023): 7771.

[361] C. Ai, L. Liu, K. Wong, X. H. Tan, and J. C. H. Goh, “The Effect of Chondroitin Sulfate Concentration and Matrix Stiffness on Chondrogenic Differentiation of Mesenchymal Stem Cells,” Biomaterials Science 11, no. 13 (2023): 4557–4573.

[362] W. Dai, Q. Liu, S. Li, et al., “Functional Injectable Hydrogel With Spatiotemporal Sequential Release for Recruitment of Endogenous Stem Cells and in Situ Cartilage Regeneration,” Journal of Materials Chemistry B 11, no. 18 (2023): 4050–4064.

[363] Y. Li, L. Li, M. Wang, et al., “O-alg-THAM/Gel Hydrogels Functionalized With Engineered Microspheres Based on Mesenchymal Stem Cell Secretion Recruit Endogenous Stem Cells for Cartilage Repair,” Bioactive Materials 28 (2023): 255–272.

[364] M. Asadikorayem, P. Weber, S. Zhang, et al., “In-situ-forming Zwitterionic Hydrogel Does Not Ameliorate Osteoarthritis in Vivo, Despite Protective Effects Ex Vivo,” Biomaterials Advances 169 (2025): 214151.

[365] H. Bliddal, J. Beier, A. Hartkopp, P. G. Conaghan, and M. Henriksen, “Polyacrylamide Gel versus Hyaluronic Acid for the Treatment of Knee Osteoarthritis: A Randomised Controlled Study,” Clinical and Experimental Rheumatology 42, no. 9 (2024): 1729–1735.

[366] H. Bliddal, J. Beier, A. Hartkopp, P. G. Conaghan, and M. Henriksen, “Effectiveness and Safety of Polyacrylamide Hydrogel Injection for Knee Osteoarthritis: Results From a 12-month Follow up of an Open-label Study,” Journal of Orthopaedic Surgery and Research 19, no. 1 (2024): 274.

[367] T. W. Kim, M. J. Chang, C. Y. Shin, C. B. Chang, and S. B. Kang, “A Randomized Controlled Trial for Comparing Efficacy and Safety Between Intraarticular Polynucleotide and Hyaluronic Acid for Knee Osteoarthritis Treatment,” Scientific Reports 13, no. 1 (2023): 9419.

[368] S. Natali, L. Farinelli, D. Screpis, et al., “Human Amniotic Suspension Allograft Improves Pain and Function in Knee Osteoarthritis: A Prospective Not Randomized Clinical Pilot Study,” Journal of Clinical Medicine 11, no. 12 (2022): 3295.

[369] A. H. Gomoll, J. Farr, B. J. Cole, et al., “Safety and Efficacy of an Amniotic Suspension Allograft Injection over 12 Months in a Single-Blinded, Randomized Controlled Trial for Symptomatic Osteoarthritis of the Knee,” Arthroscopy 37, no. 7 (2021): 2246–2257.

[370] M. J. Park, S. W. Ko, J. I. Cho, S. H. Lee, and H. K. Shin, “Effect of Intra-articular Atelocollagen Injections for Patients With Knee Osteoarthritis: A Retrospective Chart Review,” Cureus 16, no. 9 (2024): e68954.

[371] R. H. Brophy and Y. A. Fillingham, “AAOS Clinical Practice Guideline Summary: Management of Osteoarthritis of the Knee (Nonarthroplasty), Third Edition,” Journal of the American Academy of Orthopaedic Surgeons 30, no. 9 (2022): e721–e729.

[372] R. Sihvonen, M. Paavola, A. Malmivaara, et al., “Arthroscopic Partial Meniscectomy versus Sham Surgery for a Degenerative Meniscal Tear,” New England Journal of Medicine 369, no. 26 (2013): 2515–2524.

[373] R. Sihvonen, M. Paavola, A. Malmivaara, et al., “Arthroscopic Partial Meniscectomy versus Placebo Surgery for a Degenerative Meniscus Tear: A 2-year Follow-up of the Randomised Controlled Trial,” Annals of the Rheumatic Diseases 77, no. 2 (2018): 188–195.

[374] R. Sihvonen, M. Paavola, A. Malmivaara, et al., “Arthroscopic Partial Meniscectomy for a Degenerative Meniscus Tear: A 5 Year Follow-up of the Placebo-surgery Controlled FIDELITY (Finnish Degenerative Meniscus Lesion Study) Trial,” British Journal of Sports Medicine 54, no. 22 (2020): 1332–1339.

[375] S. T. Skou, E. M. Roos, M. B. Laursen, et al., “A Randomized, Controlled Trial of Total Knee Replacement,” New England Journal of Medicine 373, no. 17 (2015): 1597–1606.

[376] S. T. Skou, E. M. Roos, M. B. Laursen, et al., “Total Knee Replacement and Non-surgical Treatment of Knee Osteoarthritis: 2-year Outcome From Two Parallel Randomized Controlled Trials,” Osteoarthritis and Cartilage 26, no. 9 (2018): 1170–1180.

[377] M. Odumenya, K. McGuinness, J. Achten, N. Parsons, T. Spalding, and M. Costa, “The Warwick Patellofemoral Arthroplasty Trial: A Randomised Clinical Trial of Total Knee Arthroplasty versus Patellofemoral Arthroplasty in Patients With Severe Arthritis of the Patellofemoral Joint,” BMC Musculoskeletal Disorders [Electronic Resource] 12 (2011): 265.

[378] C. Fredborg, A. Odgaard, and J. Sørensen, “Patellofemoral Arthroplasty Is Cheaper and More Effective in the Short Term Than Total Knee Arthroplasty for Isolated Patellofemoral Osteoarthritis: Cost-effectiveness Analysis Based on a Randomized Trial,” The Bone & Joint Journal 102-b, no. 4 (2020): 449–457.

[379] B. Pongcharoen, P. Liengwattanakol, and K. Boontanapibul, “Comparison of Functional Recovery between Unicompartmental and Total Knee Arthroplasty: A Randomized Controlled Trial,” Journal of Bone and Joint Surgery American 105, no. 3 (2023): 191–201.

[380] J. Knifsund, T. Niinimaki, H. Nurmi, et al., “Functional Results of Total-knee Arthroplasty versus Medial Unicompartmental Arthroplasty: Two-year Results of a Randomised, Assessor-blinded Multicentre Trial,” BMJ Open 11, no. 6 (2021): e046731.

[381] H. J. Kwon, C. S. Kim, D. H. Kim, J. W. Shin, D. Choi, and S. S. Choi, “Effectiveness of the Cooled Radiofrequency Ablation of Genicular Nerves in Patients With Chronic Knee Pain due to Osteoarthritis: A Double-Blind, Randomized, Controlled Study,” Medicina (Kaunas, Lithuania) 60, no. 6 (2024): 857.

[382] M. L. Costa, J. Achten, N. R. Parsons, et al., “Total Hip Arthroplasty versus Resurfacing Arthroplasty in the Treatment of Patients With Arthritis of the Hip Joint: Single Centre, Parallel Group, Assessor Blinded, Randomised Controlled Trial,” Bmj 344 (2012): e2147.

[383] J. Achten, N. R. Parsons, R. P. Edlin, D. R. Griffin, and M. L. Costa, “A Randomised Controlled Trial of Total Hip Arthroplasty versus Resurfacing Arthroplasty in the Treatment of Young Patients With Arthritis of the Hip Joint,” BMC Musculoskeletal Disorders [Electronic Resource] 11 (2010): 8.

[384] J. J. Young, M. G. Zywiel, S. T. Skou, et al., “Total Hip Arthroplasty versus Education and Exercise: A Propensity-Matched Analysis of 266 Patients Who Have Hip Osteoarthritis,” Journal of Arthroplasty 39, no. 9s2 (2024): S261–s269.

RIGHTS & PERMISSIONS

2026 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.